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ABSTRACT

Alterations of NMDA and GABAB Receptor Function in Development: A Potential
Animal Model of Schizophrenia
by
Monica Bolton
Dr. Jefferson Kinney, Examination Committee Chair
Assistant Professor of Psychology
University of Nevada, Las Vegas
Schizophrenia is a debilitating mental disorder that affects up to 3% of the world
population. The behavioral symptoms are categorized into positive and negative
symptoms, which appear during late adolescence/early adulthood. Unfortunately, the
underlying cellular and molecular mechanisms of the disease are poorly understood.
Several hypotheses exist to explain mechanisms contributing to these behavioral
alterations. One model proposes that a reduced function of the NMDA glutamate receptor
on specific GABAergic interneurons may be responsible for deficits in schizophrenia.
Post-mortem investigations provide evidence of reductions in both glutamate and GABArelated proteins in patients with schizophrenia. Further, GABAergic interneurons that are
activated by glutamate via NMDA receptors are important for oscillatory activity
involved with sensory processing and cognitive function. Alterations in the function of
NMDA receptors on GABAeric interneurons are implicated in regulating neural network
activity and, if disrupted, could potentially lead to altered brain function and deficits seen
in schizophrenia. Several investigations have demonstrated reduction in NMDA receptor
function or GABA receptor function induces deficits consistent with schizophrenia.
Recent approaches have also focused on changes in NMDA or GABA function related to
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schizophrenia as a neurodevelopmental disorder. This approach suggests that alterations
in either system during brain development may result in behavioral deficits later in life.
The purpose of the below studies was to determine if changes in NMDA receptor
function or alterations in downstream GABA receptor function during development in
rodent pups results in behavioral or biochemical alterations in adulthood that are relevant
to schizophrenia. The data reveal that altering these receptor systems in development
produce deficits in adulthood. Changes in sensorimotor gating, spatial learning and
memory, and differential expression of multiple GABA related proteins in the brain
tissue were observed in these animals.

iv

TABLE OF CONTENTS
ABSTRACT ....................................................................................................................... iii
LIST OF FIGURES .......................................................................................................... vii
CHAPTER 1 INTRODUCTION ........................................................................................ 1
CHAPTER 2 REVIEW OF RELATED LITERATURE .................................................... 5
Schizophrenia ...................................................................................................... 5
Glutamate Hypothesis of Schizophrenia ............................................................. 7
GABA Signaling ............................................................................................... 10
Neurodevelopmental Approaches ..................................................................... 20
Hypotheses and Implications ............................................................................ 27
CHAPTER 3 MATERIALS AND METHODS ............................................................... 30
Subjects ............................................................................................................. 30
Drug Treatments ................................................................................................ 30
Apparatus .......................................................................................................... 31
Prepulse Inhibition of Acoustic Startle ................................................. 31
Fear Conditioning Chambers ................................................................ 31
Morris Water Maze ............................................................................... 32
Tail Flick ............................................................................................... 32
Drug Administration ......................................................................................... 33
Behavioral Testing ............................................................................................ 33
Prepulse Inhibition of Acoustic Startle ................................................. 33
Cued and Contextual Fear Conditioning ............................................... 34
Morris Water Maze ............................................................................... 35
Tail Flick ............................................................................................... 36
Tissue Analysis ................................................................................................. 37
Tissue Collection ................................................................................... 37
SDS-PAGE Western Blotting ............................................................... 37
Statistical Analysis ............................................................................................ 39
CHAPTER 4 RESULTS ................................................................................................... 40
Behavioral Testing ............................................................................................ 40
Prepulse Inhibition of Acoustic Startle ................................................. 40
Cued and Contextual Fear Conditioning ............................................... 44
Morris Water Maze ............................................................................... 50
Tail Flick ............................................................................................... 55
Tissue Analysis ................................................................................................. 56
SDS-PAGE Western Blotting ............................................................... 56
v

CHAPTER 5 DISCUSSION ............................................................................................. 62
REFERENCES ................................................................................................................. 79
VITA ............................................................................................................................... 103

vi

LIST OF FIGURES
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14

Comparison of Rat and Human Brain Development ................................... 25
Acoustic Startle Responses.......................................................................... 41
Percent Prepulse Inhibition with 100 ms ISI ............................................... 42
Percent Prepulse Inhibition with 40 ms ISI ................................................. 43
Day 1 CCF Training .................................................................................... 44
Cued Fear Day 2 and Contextual Fear Day 3 .............................................. 46
Cued Fear Day 4 and Contextual Fear Day 5 .............................................. 47
Cued Fear Day 6 and Contextual Fear Day 7 .............................................. 48
Morris Water Maze Latency and Probe Trial .............................................. 53
Swim Speed and Thigmotaxis ..................................................................... 54
Tail Flick Latency........................................................................................ 55
GABA Receptor Protein Levels .................................................................. 58
GAD67 Protein Levels ................................................................................ 60
NR2B and Kalirin Protein Levels................................................................ 61

vii

CHAPTER 1
INTRODUCTION
While the etiology of schizophrenia is not known, several behavioral symptoms
exist that characterize the disorder. Patients suffer from a combination of symptoms
including hallucinations and delusions (positive symptoms), as well as deficits in
sensorimotor gating, learning, and memory (negative symptoms) and others. Although
the symptoms appear during early adulthood or late adolescence, the disorder may
originate from an unknown neurodevelopmental abnormality (Weinberger, 1987).
Numerous studies have been carried out in order to better understand the cellular and
molecular basis of this disease in order to effectively treat patients.
One of the current hypotheses to explain the pathophysiology of schizophrenia
proposes that there is a reduction in glutamate and γ-aminobutyric acid (GABA)
signaling in the brain. Specifically, a reduction of the N-methyl-D-aspartate (NMDA)type glutamate receptor function on GABAergic interneurons produces altered network
function and deficits associated with schizophrenia (Javitt, 2007). Administering drugs
which block the NMDA receptor in healthy individuals produces behavior that is similar
to the positive and negative symptoms observed in schizophrenic patients, and these
drugs exacerbate symptoms in schizophrenic patients (Adler et al., 1999; Javitt & Zukin,
1991; Krystal et al., 1994; Lahti et al., 1995; Luby et al., 1962). Post-mortem
investigations of schizophrenia populations also reveal a reduction in specific subunits of
the NMDA receptors and several protein markers associated with GABAergic
interneurons (Benes & Berretta, 2001; Bullock et al., 2008; Hashimoto et al., 2003;
Mirnics et al., 2000; Torrey et al., 2005). These proteins include glutamate decarboxylase
1

67 (GAD67; enzyme required for GABA synthesis; Akbarian et al., 1996; Kaufman,
Houser, & Tobin, 1991; Volk et al., 2000) and parvalbumin (PV; a calcium binding
protein; Beasley & Reynolds, 1997). Many behaviors depend on the activation of
GABAergic interneurons via glutamate binding to NMDA receptors including network
oscillations involved in learning and memory and cognitive function, as well as the
development of neural networks during brain development.
GABA signaling is imperative for initiating and maintaining neural network
oscillations (Gonzalez-Burgos & Lewis, 2008). Data suggests that the negative symptoms
and cognitive deficits seen in schizophrenic patients may arise from abnormal oscillatory
activity (Gonzalez-Burgos, 2010; Lewis, Hashimoto, & Volk, 2005; Uhlhaas & Singer,
2010). NMDA receptor hypofunction on GABAergic cells could result in a reduced
amount of GABA release. GABA release from these neurons inhibits a large population
of downstream postsynaptic excitatory neurons, allowing them to become entrained into a
synchronous firing pattern once the inhibition subsides (Roopun et al., 2008). GABA
binds to both ionotropic (mainly GABAA) and metabotropic (GABAB) receptors. Binding
to GABAA receptors results in fast-acting and short-lived inhibition (Macdonald & Olsen,
1994; Watanabe et al., 2002) whereas activation of GABAB receptors results in a slower
onset but long-lasting inhibitory effect (Kerr & Ong, 1992). The GABAB receptors have
been shown to be important in maintaining oscillatory activity due to their sustained
inhibitory properties (Scanziani, 2000). A reduction of GABA release or binding to
receptors could result in asynchronous firing and possibly the abnormal oscillatory
activity seen in schizophrenia patients.
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Animal models of schizophrenia provide valuable insight into the mechanisms
that may be involved in the disorder. Administration of ketamine (an NMDA receptor
antagonist) to adult rodents produces deficits in sensorimotor gating, spatial learning and
memory, and fear associative learning similar to what is seen in the patient population
(Bolton et al., 2012; Cilia et al., 1997; de Bruin et al., 1999; Mansbach and Geyer, 1991;
Sabbagh et al., 2012). Drugs that alter GABAB receptor function are less well studied in
learning and memory and have been largely excluded for any potential role in
schizophrenia. A limitation in the above studies is that they rely on drug being active at
the time of testing. An alternative approach that may also allow investigators to
incorporate the developmental theory of schizophrenia would be to administer drugs that
target this system during development and test for behavior in adulthood.
A wealth of data examining brain morphology, protein expression changes,
genetics, environmental factors, and gene-environment interactions suggests that some of
the pathology leading to schizophrenia occurs during early brain development (Fatemi &
Folsom, 2009; Lewis & Levitt, 2002; Lewis et al., 2004; Rapoport et al., 2005;
Weinberger, 1987; Weinberger & Lipska, 1995). NMDA receptors and GABA signaling
contribute

to

major

developmental

processes

including

neuronal

migration,

synaptogenesis, and incorporation of neurons into neural networks (Komuro & Rakic,
1993; LoTurco, Blanton, & Kriegstein, 1991; Uhlhaas et al., 2010). An alteration in these
receptor systems at critical brain developmental periods may have particular relevance to
behavioral disturbances.
The purpose of this study was to determine if disrupting the function of NMDA or
GABAB receptors in early life produces deficits consistent with schizophrenia in
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adulthood. Our data demonstrate that a brief pharmacological alteration in NMDA
receptor function and, separately, GABAB receptor function during early brain
development of rat pups, results in altered behavior in adulthood in tasks that measure
sensorimotor gating (using prepulse inhibition) and spatial learning in the Morris water
maze. The most striking differences in these studies were differences between males and
females receiving the same treatments, specifically the GABAB receptor antagonist
(phaclofen) producing the most robust deficits. We also identified numerous changes in
the tissue analysis in GABA related proteins as well as a marker for synaptic formation.
These results suggest that alterations in of NMDA and GABAB receptors in brain
development can produce lifelong impairments that may be related to neuropsychiatric
disorders.

4

CHAPTER 2
REVIEW OF RELATED LITERATURE
Schizophrenia
Schizophrenia is a debilitating brain disorder which affects up to 1-3% of the
population with symptoms that cause lifelong impairments and disability (Rossler et al.,
2005). The clinical diagnosis is usually made in late adolescence or early adulthood when
the symptoms typically first occur. These symptoms manifest into a constellation of
behavioral abnormalities that are classified into either positive or negative subgroups.
Characteristics of the positive symptoms include auditory hallucinations, delusions, and
paranoia (Kay et al., 1987). Negative symptoms can be described as a deficit compared to
the normal population. They leave patients with impairments in sensorimotor gating,
attention, abstract reasoning, mental flexibility, learning and memory, affect, and certain
aspects of information processing (Carter et al., 1996; Rushe et al., 1999; Swerdlow et al.,
1994). Because of these deficits, patients are left with a lifetime disability in a variety of
everyday functional and social domains (Burns, 2007; Green, Kern, Braff, & Mintz,
2000). Unfortunately, the etiology of schizophrenia is not known but there have been
various cellular/molecular mechanisms proposed to account for the disorder.
Several neurochemical hypotheses have been suggested to explain the
pathophysiology of schizophrenia. The discovery of dopamine antagonists’ utility as an
antipsychotic in the late 1950s suggested that dopamine has a role in the disorder.
Dopamine is a monoamine neurotransmitter and has been shown to mediate multiple
systems within the central nervous system (CNS); most importantly, it plays a major role
in reward systems (Schultz, Dayan, & Montague, 1997) and motor function
5

(Korchounov, Meyer, & Krasnianski, 2010). The specific role of dopamine in
schizophrenia remains to be identified; however, data indicate that antipsychotics
alleviate positive symptoms by modifying dopamine receptor function, which suggests a
dysregulation of dopamine in schizophrenia. Investigations of dopamine alterations in
schizophrenia populations include the evaluation of post-mortem tissue, imaging in
patient populations, and numerous animal models of dopamine dysfunction relevant to
the disorder (Bird et al., 1977; Crow et al., 1979; Davis, Kahn, Grant, & Davidson, 1991;
Elkashef et al., 2000; Haberland & Hetey, 1987; Howes & Kapur, 2009; Toru,
Nishikawa, Mataga, & Takashima, 1982). Data from these studies have provided mixed
evidence for altered dopamine in discrete brain regions as being associated with
schizophrenia. These data also have provided the foundation for what is termed the
dopamine hypothesis (Carlsson, 1988; van Rossum, 1966), which argues that elevated
dopamine activity in subcortical regions (the striatum and basal ganglia) is associated
with the positive symptoms of schizophrenia, while reduced dopamine activity within the
cortex may be associated with the negative symptoms (Davis et al., 1991; Pycock,
Kerwin, & Carter, 1980). However, limitations to this theory exist. For instance, the
means by which dopamine tone is elevated in some regions and reduced in others has not
been elucidated. Additionally, antipsychotic medications only moderately alleviate the
positive symptoms and have limited efficacy for the negative symptoms (Javitt & Zukin,
1991). Although dopamine tone is altered in schizophrenia, the dopamine hypothesis
does not account for the cause of these changes.
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Glutamate Hypothesis of Schizophrenia
A more recent alternative model hypothesized to explain the cellular/molecular
alterations in schizophrenia is based on a combination of data from drug abuse literature
and separate post-mortem examinations of schizophrenia populations. The model
proposes that there is a reduction in glutamate signaling within discrete circuits of the
brain, which may account for the behavioral symptoms of schizophrenia and also may
cause alterations in

dopamine signaling.

Glutamate is the main excitatory

neurotransmitter in the brain. Activation of glutamatergic receptors results in excitation
of both excitatory and inhibitory neurons through a variety of receptors, including the
NMDA receptor. The initial investigation of the NMDA receptor as it relates to
schizophrenia began with individuals who abused drugs that block these receptors
(ketamine and phencyclidine; NMDA receptor antagonists). The effects of the abuse of
these drugs as well as observations from previous studies with controlled administration
of NMDA receptor antagonists to healthy volunteers showed that NMDA receptor
antagonists are capable of mimicking the cognitive and behavioral symptoms of
schizophrenia in healthy individuals (Adler et al., 1999; Krystal et al., 1994; Luby et al.,
1962). Additionally, abuse of ketamine or phencyclidine (PCP) by schizophrenic patients
has been demonstrated to exacerbate schizophrenia symptoms and produce psychosis in
stable patients (Javitt, 1987; Lahti et al., 1995; Luby et al., 1962). These early
observations provide support that the NMDA receptor may be involved in the disorder.
NMDA receptors play an important role in learning and memory, cognition, and
sensory processing. In the hippocampus, NMDA receptors are necessary for long-term
potentiation (LTP), a process in which the synaptic connections between two or more
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neurons that fire together are strengthened (Bliss & Lomo, 1973; Bliss & Collingridge,
1993; Hebb, 1949). This process is hypothesized to be vitally important for learning and
memory and is strongly linked to new memory formation. Pharmacologically blocking
the function of NMDA receptors leads to impaired cognition, learning, immediate recall,
and long-term retention (Lee et al., 1993; Ohno, Yamamoto, & Watanabe, 1994).
NMDA receptors are unique because they are both ligand and voltage-gated
receptors. While the binding of glutamate and glycine to the NMDA receptor will induce
a conformational change in the receptor, the presence of a magnesium (Mg+) ion bound
to the inside of the channel at resting membrane potential (-65 mV) prevents the passage
of any ions through the channel. When the membrane is depolarized by non-NMDA
glutamate receptors (AMPA and kainite), the Mg2+ ion is driven out of the channel by
electrostatic repulsion, allowing the channel to open and calcium (Ca2+) to enter (Mayer,
Westbrook, & Guthrie, 1984; Nowak et al., 1984). The influx of Ca2+ into the cell leads
to an increase in membrane potential, as well as the activation of a variety of Ca2+
dependent second messenger systems (Kleinschmidt, Bear, & Singer, 1987). Therefore,
activation of the NMDA receptor requires a unique combination of ligand binding and
membrane depolarization.
NMDA receptors are composed of subunits termed NR1, NR2, and NR3. All
functional NMDA receptors contain one NR1 subunit and either one of several possible
subunits of NR2 (NR2A-D) or NR3 (Monyer et al., 1992). Different subunit assemblies
of NMDA receptors contribute different functional properties of the receptor, including
the strength of the Mg2+ block, glycine sensitivity, and receptor occupancy (Ishii et al.,
1992; Kutsuwada et al., 1992; Monyer et al., 1992). For example, NR1-NR2A and NR1-
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NR2B channels are characterized by a stronger voltage sensitivity of the Mg2+ block (it
takes a greater voltage change to dislodge the ion) compared to NR1-NR2C and NR1NR2D channels (Monyer et al., 1992). Because of the weaker Mg2+ block seen in the
latter receptor channels, their function may be to detect relatively small postsynaptic
depolarizations. Another functional difference between subtype assemblies is that NR2Acontaining receptor channels do not bind glutamate for very long (measured by offset
decay time) compared to the other subtypes (Monyer et al., 1992). Consequently, NR1NR2B, NR1-NR2C, or NR1-NR2D receptors mediate longer-duration excitatory
postsynaptic potentials as compared to NR1-NR2A receptors. Throughout a lifespan, the
assembly of NMDA receptors differs (Akazawa et al., 1994). During development, NR1
and all NR2 subunits are expressed at peak levels on postnatal day (PND) 7 in the rat
brain (about third trimester for human brain development; Clancy et al., 2007); then, after
PND 12, a distinct change in expression occurs for the NR2 subunits (Monyer et al.,
1994). There is a shift from the expression of NR2B and NR2D subunits, both of which
are most abundant in the neonatal brain, to the expression of NR2A in the forebrain and
NR2C in the cerebellum (Akazawa et al., 1994; Cull-Candy, Brickley, & Farrant, 2001;
Monyer et al., 1994). Since many important cognitive processes depend on the NMDA
receptors, altering their assembly and thus their activity can cause devastating effects.
Alongside the previously mentioned drug abuse literature, complementary data
from post-mortem examinations of schizophrenic patients have given further valuable
insight into the possible glutamatergic changes that occur in the disorder. Not only is
glutamatergic tone reduced in schizophrenia patients (Sherman et al., 1991; Squires et al.,
1993), differential expression of mRNA for the NR2A (increased levels) and NR2D

9

(decreased levels) subunits has been observed in the prefrontal cortex (Akbarian et al.,
1996). Additional changes include a reduction the NR1 subunit in the hippocampus
versus healthy controls (Gao et al., 2010). These data suggest that not only is there an
overall reduction in glutamate signaling, but there is also an alteration in the assembly
and function of the NMDA receptor.
GABA Signaling
GABA is the main inhibitory neurotransmitter in the brain and is synthesized
from glutamate by GAD67. GABAergic interneurons are responsible for inhibitory
signaling that is vital for normal CNS function, including the regulation of network
oscillatory activity. A necessary component of the activation of these GABAergic
neurons comes from NMDA receptors. When glutamate binds, the receptors allow Ca2+
to enter causing the cell to depolarize and release GABA. These interneurons are very
large compared to pyramidal neurons and connect onto many different excitatory
postsynaptic neurons (e.g. dopamine, serotonin, glutamate). The rapid release of GABA
onto the postsynaptic excitatory neurons produces a sustained inhibition. This inhibition
entrains the postsynaptic neurons into a synchronous firing pattern and, once disinhibited
(removal of inhibition), the neurons are then allowed to fire when receiving excitatory
input from other cells. Based on the role of NMDA receptor function, it has been
hypothesized that NMDA receptor-mediated excitation of GABAergic interneurons
results in the inhibitory activity that drives network function. Numerous investigations
have shown that NMDA receptors on inhibitory GABAergic interneurons are
disproportionately more sensitive to NMDAR antagonists (Coyle, Tsai, & Goff, 2003;
Grunze et al., 1996; Li, Clark, Lewis, & Wilson, 2002) and, more specifically, those that
10

contain PV may have relevance to schizophrenia (Beasley & Reynolds, 1997; Beasley e
al., 2002; Coyle et al., 2003; Kinney et al., 2006; Morris, Cochran, & Pratt, 2005;
Reynolds et al., 2001). These data suggest that a reduction in the function of NMDA
receptors can cause a lack of inhibition in discrete brain regions that have PV+
GABAergic interneurons. The effect of this lack of inhibition is proposed to cause a
disruption in the synchronous activity of downstream excitatory pyramidal neurons.
GABAergic interneurons play an important role in the generation and entrainment
of oscillations (Gonzalez-Burgos, 2010); therefore, neuronal synchronization is thought
to rely on GABA-mediated inhibition. Gamma- and theta-wave oscillatory activity is
suggested to underlie working memory and information processing between cortical areas
and is related to cognitive function (Bartos, Vida, & Jonas, 2007; Cardin et al., 2009;
Fries, 2009; Gonzalez-Burgos & Lewis, 2008; Roopun et al., 2008; Salinas & Sejnowski,
2001; Sohal et al., 2009; Uhlhaas & Singer, 2010). Based on numerous studies, the
cognitive deficits seen in schizophrenia may result from abnormal neuronal oscillatory
activity (Gonzalez-Burgos, 2010; Lewis et al., 2005; Uhlhaas & Singer, 2010).
Converging evidence suggests that the generation of oscillations, which are impaired
during cognitive tasks in schizophrenic patients (Minzenberg et al., 2010; Spencer et al.,
2004; Woo, Spencer, & McCarley, 2010), depends on NMDA receptor-mediated
transmission on PV+ GABAergic interneurons (Phillips et al., 2012; Sohal et al., 2009).
Each PV+ GABAergic interneuron projects onto many excitatory neurons and
disinhibition from one interneuron can desynchronize the majority of a local network,
leading to a disruption in cortical processing (Moghaddam et al., 1997; Phillips et al.,
2012). Decreased expression of PV leads to increased asynchronous release of GABA
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from PV+ GABAergic interneurons, which may result in a reduction in the ability of
downstream excitatory neurons to integrate incoming stimuli, the functional consequence
of which may be altered cognitive function and sensory processing (Javitt, 2009; Powell,
Sejnowski, & Behrens, 2012; Uhlhaas & Singer, 2010). Although data provide evidence
for a reduction in NMDA receptors and PV expression, the GABA receptors themselves
may also play a role in desynchronization as it relates to schizophrenia.
GABA binds to both ionotropic and metabotropic receptors in the central nervous
system. Ionotropic GABA receptors (mainly GABAA) are ligand-gated ion channels
permeable to chloride. Once GABA binds and activates these ionotropic channels, a fast
acting inhibitory current is produced within the cell (Macdonald & Olsen, 1994).
Conversely, the metabotropic GABA receptors (GABAB) are G-protein coupled receptors
that are located both pre- and postsynpatically and produce a slow onset but longer
lasting inhibition (Couve, Moss, & Pangalos, 2000; Kerr & Ong, 1992). Presynaptic
GABAB receptors suppress neuronal Ca2+ conductance, leading to the inhibition of
neurotransmitter release of the presynaptic neuron. Postsynaptic GABAB receptors
increase membrane conductance to potassium (K+) leading to the hyperpolarization of
postsynaptic neurons (Bettler e al., 2004; Bowery et al., 2002; Kohl & Paulsen, 2010;
Misgeld, Bijak, & Jarolimek, 1995; Padgett & Slesinger, 2010). Functional GABAB
receptors exist as heterodimers (Jones et al., 1998) comprised of a GABABR1 (contains
binding site) and a GABABR2 subunit (contains regulatory G-proteins; Bowery et al.,
2002; Galvez et al., 2001; Kohl & Paulsen, 2010; Pinard, Seddik, & Bettler, 2010;
Robbins et al., 2001). Compared to the function of the GABAB receptor, the function of
the GABAA receptor is better understood because of its direct activation and fast
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inhibition properties. Both GABAA and GABAB receptors are able to modulate GABA
oscillations and LTP, which results in altered learning and memory functions (Scanziani,
2000).
Although the distinct roles the GABA receptors play in cognitive functions such
as learning and memory are unclear, in vivo and in vitro studies have shown they are able
to modulate neuronal oscillations. For instance, simultaneously blocking GABAA and
GABAB receptor function in vitro facilitates theta frequency oscillations induced by a
cholinergic agonist (Konopacki et al., 1997). Data from transgenic animals and
pharmacological studies demonstrate that the GABAB receptor is vital for the stability of
cortical circuits, possibly due to the longer lasting inhibitory properties of these receptors.
GABABR1 knockout mice develop spontaneous seizures and premature death (Prosser et
al., 2001; Schuler et al., 2001); meanwhile, high doses of GABAB receptor antagonists
administered to adult rodents induce hippocampal and neocortical seizures (Leung,
Canning, & Shen, 2005; Vergnes et al., 1997). However, the data regarding cognitive
task performance and learning and memory are limited and inconsistent. Several studies
indicate that low dose GABAB receptor antagonists enhance (Getova & Bowery, 2001;
Helm et al., 2005; Leung & Shen, 2007; Mondadori, Jaekel, & Preiswerk, 1993;
Mondadori, Mobius, & Borkowski, 1996; Staubli, Scafidi, & Chun, 1999) or do not alter
cognitive task performance compared to controls (Zarrindast et al., 2002). Studies using
GABAB receptor agonists are similarly inconsistent and sometimes contradictory
(Myhrer, 2003). The incongruent results from GABAB receptor ligands may be due to the
fact that the receptors are located both pre, post, and extrasynaptically and any functional
effect of the ligand may not produce straightforward results.
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Similar to what is found in post-mortem investigations with NMDA receptor
subunits, GABAB receptors are also decreased in the prefrontal cortex and hippocampus
of schizophrenic patients (Ishikawa et al., 2005; Mizukami et al., 2000; Mizukami et al.,
2002). Post-mortem analysis in schizophrenia populations have shown consistent
alterations in GAD67 and PV expression in the hippocampus and prefrontal cortex
(Beasley & Reynolds, 1997; Benes et al., 1991; Bullock et al., 2008; Hashimoto et al.,
2003; Mirnics et al., 2000; Reynolds, Zhang, & Beasley, 2001; Torrey et al., 2005). Since
both of these proteins are specific to GABAergic interneurons, these data suggest that
GABA signaling may be altered in the disorder as well.
As previously discussed, the hypofunction of NMDA receptors may result in the
disinhibition of GABAergic interneurons. It is also possible that the receptors to which
GABA binds may be differentially expressed, such that a similar disinhibition occurs. If
there is a reduction in pre- or postsynaptic GABAB receptor function, an alteration in the
release or binding of GABA potentially results in asynchronous activity. Disrupting the
function of either NMDA receptors or GABAB receptors could conceivably result in the
same change in oscillatory activity that has been speculated to occur in schizophrenia.
Animal Systems to Model Mechanisms of Schizophrenia
Although schizophrenia is an inherently human disorder, certain symptoms can be
tested in rodent models. For instance, prepulse inhibition to test for sensorimotor gating is
often examined in animal models of schizophrenia, as well as to test the potential efficacy
of novel antipsychotics (Swerdlow, Braff, & Geyer, 2000). Additionally, the Morris
water maze is utilized to look for spatial learning and memory deficits and cued and
contextual fear conditioning is used to investigate associative fear learning. As noted
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above, schizophrenia patients exhibit deficits in all of these tasks, suggesting the
impairments may have relevance to the disorder.
Sensorimotor gating can be described as the ability to filter extraneous noise from
meaningful sensory inputs (Freedman et al., 1987). Patients have been characterized as
being hypervigilant and sensitive to distracting sounds whereby their inability to gate
stimuli makes them feel “flooded” by sensory stimulation (Venables, 1964).
Sensorimotor gating can be measured in a task called prepulse inhibition (PPI) in both
human and animals. PPI refers to the normal reduction of a startle response when a
startling stimulus is preceded by a weaker, non-startling stimulus (prepulse). The theory
is that the prepulse evokes an inhibitory response of the motor reflex that reduces the
response to the startle stimulus (Braff & Geyer, 1990; Swerdlow, Geyer, & Braff, 2001).
PPI is observed in neuropsychiatric disorders and can be modulated by drugs of abuse
(Braff & Geyer, 1990; Geyer & Braff, 1987). Since PPI occurs on the first exposure of a
prepulse-startle trial, it does not reflect a learned behavior but a reflexive response
(Fendt, Li, & Yeomans, 2001; Graham, 1975; Hoffman & Wible, 1970; Ison, McAdam,
& Hammond, 1973; Koch, 1999). Patients with schizophrenia startle similarly regardless
of whether the startle stimulus is preceded by a non-startling, weaker prepulse, suggesting
the prepulse does not inhibit this reflexive response as seen in healthy controls (Geyer &
Braff, 1987). This disruption in PPI suggests a failure in sensorimotor gating that may
result from stimulus over-flow either from the external environment and/or from within
the subject itself.
Mediating brain regions for PPI of the startle reflex are found mostly within the
brain stem. Briefly, the acoustic prepulse is relayed from the inferior and superior
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colliculus to the pedunculopontine tegmental nucleus, with lesser contributions to the
circuit from the laterodorsal tegmental nucleus and substantia nigra, pars reticulata.
Activation of the midbrain nuclei by the prepulse is converted into long-lasting inhibition
of the giant neurons in the caudal pontine reticular nucleus, with the involvement of
GABAB receptors contributing to the inhibition of the startle response (Fendt et al., 2001;
Swerdlow et al., 2001). Other regions are shown to regulate the brain circuitry
responsible for PPI, including the hippocampus and the prefrontal cortex, which have
subcortical projections to the nucleus accumbens and ventral tegmentum (Swerdlow et
al., 2001). Both NMDA and GABAB receptors contribute to this circuit and altering these
receptors produces PPI deficits. This task is foundational as a preclinical behavioral test
for animal models of schizophrenia.
Another task used in research on animal models of schizophrenia to evaluate
learning and memory deficits is the Morris water maze. Spatial learning and memory is
disrupted in schizophrenic patients and it has been measured using a virtual, computerbased water maze task (Folley et al., 2010; Hanlon et al., 2006). The original Morris
water maze was developed for rodents and consists of a circular tank filled with opaque
water and a submerged escape platform that is not visible. In order to locate the hidden
platform using a spatial strategy, the animal must use spatial cues that are located outside
the maze. Across days, control animals begin to utilize a spatial strategy that depends on
the extra maze cues, which results in decreased latencies (time) to find the platform. To
determine how well the animals learned the task, a probe trial is conducted in which the
platform is removed and animals swim for a full trial period. Depending on how well
they learned the task, the animals should spend most of their time in the area of the maze
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where the platform was located. Performance in the water maze is disrupted after
hippocampal lesions (Amaral & Witter, 1991; Moser, Moser, & Andersen, 1993) where
both NMDA and GABAB receptors are prevalent (Dutar & Nicoll, 1988; Monaghan,
Andaloro, & Skifter, 1998; Sakurai, Penney, & Young, 1993).
Patients with schizophrenia exhibit deficits in emotional processing and emotional
learning and memory (Hall et al., 2007). The deficits resemble those found in patients
with amygdalae damage (Aleman et al., 2007; Hall et al., 2007; Kosaka et al., 2002;
Whalley et al., 2009). For example, patients with schizophrenia have reduced activation
of the amygdala when viewing emotional faces, as well as an alteration in hippocampal
activity when viewing emotional scenes compared to control individuals (Hall et al.,
2007). Pavlovian fear conditioning is a type of associative learning task that has been
utilized to test for deficits in emotional learning and memory in animal systems (Bolton
et al., 2012; Kinney et al., 2002; Phillips & LeDoux, 1992). By pairing a neutral stimulus
such as a tone (conditioned stimulus; CS) with one that elicits a fear response such as a
mild foot shock (unconditioned stimulus; US), the CS will eventually elicit a similar fear
response (freezing behavior in rodents) without the presence of the US. This association
can be quantified using the fear response to the CS and serve as a measure of how well an
animal learns the association. After training, the animal can be placed in a novel
environment with the presentation of the original CS to determine the cued fear
association (association of fear to the tone) or the animal can be placed in the original
training environment with no CS presentations to demonstrate contextual fear association
(association of fear to the environment). Different neural mechanisms and regions govern
the associations utilized in this task depending on how the CS and US are presented
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during training. In the standard delay cued and contextual fear (CCF) procedure, the CS
and the US overlap in time and co-terminate. This training protocol requires amygdala
activation to make the cued fear association (Davis & Whalen, 2001; Kinney et al., 2002;
LeDoux et al., 1990; Phillips & LeDoux, 1992; Schafe et al., 2001) and the contextual
fear association is dependent on the hippocampus (Chen et al., 1996; Holland & Bouton,
1999; Kinney et al., 2002; Logue, Paylor, & Wehner, 1997; R. G. Phillips & LeDoux,
1992). Manipulating the training protocol by inserting a temporal gap between the
cessation of the CS and the onset of the US (trace CCF procedure) makes the task more
difficult and more presentations of the CS and US are required to learn the association
(Beylin et al., 2001; Kinney et al., 2002). Also, both the hippocampus and amygdala
become imperative to make the cued fear association (Bolton et al., 2012; Kinney et al.,
2002; McEchron et al., 1998; 2000; Moyer, Deyo, & Disterhoft, 1990; Ryou, Cho, &
Kim, 2001; Solomon et al., 1986; Sutherland & McDonald, 1990; Weiss et al., 1999)
while contextual fear is still dependent on the hippocampus (Bolton et al., 2012; Chen et
al., 1996; Holland & Bouton, 1999; Kinney et al., 2002; Logue et al., 1997; Phillips &
LeDoux, 1992). Manipulations that result in differences in fear responses can reveal
deficits in the mechanisms associated with different brain regions.
The above behavioral tasks are used to measure learning and memory deficits in
rodents with relevance to those observed in the schizophrenia population. NMDA
receptor antagonists have been used in animal models to investigate symptoms associated
with schizophrenia. As previously mentioned, these antagonists include PCP, ketamine,
as well as MK-801. Although PCP produces more potent and longer lasting effects than
the other NMDA antagonists, low doses of ketamine (subanesthetic doses) induce
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changes in cortical GABAergic activity that result in disinhibition (Behrens et al., 2007).
Subanesthetic doses of ketamine in adult rodents produce sensorimotor gating deficits as
measured by PPI (Bolton et al., 2012; Braff & Geyer, 1990; Sabbagh et al., 2012), as well
as behavioral alterations in the Morris water maze (Becker et al., 2003; Moosavi et al.,
2012; Sabbagh et al., 2012), and CCF (Bolton et al., 2012). Since blocking NMDA
receptors on GABAergic interneurons produces a reduction in GABAergic tone due to
diminished firing, an alternative approach to achieve a similar effect would be to alter
GABA receptor function. As opposed to GABAA receptors whose responses are short
lived, GABAB receptors provide the long lasting inhibition seen in oscillatory activity.
However, drugs that target GABAB receptors are less utilized in schizophrenia research
compared to NMDA receptor antagonists. As mentioned previously, GABAB receptor
ligands administered to animals results in inconsistent behavior in learning and memory
tasks (Myhrer, 2003). These inconsistencies may result because GABAB receptors are
located pre, post, and extrasynaptically; further, the effect of the ligands may also rely on
the task utilized. Our laboratory has demonstrated that administering a GABAB receptor
agonist (baclofen) produces deficits in CCF (Heaney et al., 2012), and preliminary data
suggest PPI deficits. While this approach to modeling schizophrenia has been productive
in demonstrating potential mechanisms involved in the disorder, one drawback is that
these deficits are only present when the drug is active in the animal’s system. Therefore,
it may be relevant to determine if alterations during development produce similar deficits
without administering drugs at the time of behavioral testing.
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Neurodevelopmental Approaches
Based on the typical age of diagnosis of schizophrenia and the overlap of this time
point with several developmental processes, schizophrenia is suggested to be the result of
disturbances in early brain development. Multiple proposed models argue that a change
in developmental trajectory results in schizophrenia, which is not evident until early
adulthood (Fatemi & Folsom, 2009; Lewis & Levitt, 2002; Lewis et al., 2004; Rapoport
et al., 2005; Weinberger, 1987; Weinberger & Lipska, 1995). Studies that support this
approach focus on post-mortem tissue analysis of patients with schizophrenia and the
genetic and/or environmental stressors.
Post-mortem tissue analysis reveals that there are changes in specific circuits in the
brain related to subtle variations during development. These investigations have found
cytoarchitectural disorganization in the hippocampus with too few neurons in the
superficial layers and too many neurons in deeper layers (Jakob & Beckmann, 1986).
This study has since been replicated using similar methodology and extended into the
prefrontal, temporal, and limbic cortices with the same results (Akbarian et al., 1996;
Arnold et al., 1991; Benes et al., 1991). This cytoarchitectural disorganization suggests a
failure of neuronal migration and inappropriate final placement of neurons, an event that
occurs during early development. In normal brain development, the migration of neurons
to these regions occurs during the second trimester of intrauterine development (Rakic,
1988). The disorganization of this process could potentially result in altered connectivity
of these regions. Additionally, other post-mortem studies of patients with schizophrenia
indicate there are no signs of neuronal damage (Falkai & Bogerts, 1986) and no sign of
progressive worsening of the pathology over time, indicating that the cytoarchitecture

20

disorganization in schizophrenic patients must occur during development (Weinberger,
1987; Weinberger & Lipska, 1995). The cause of the alterations in post-mortem tissue is
not known but several potential mechanisms have been proposed.
The initial disturbances during development might be triggered by a combination of
genetic and/or environmental stressors. A number of susceptibility genes are associated
with schizophrenia. For instance, the gene that encodes for the protein Reelin is reduced
in the brains of patients with schizophrenia (Beffert et al., 2005; Impagnatiello et al.,
1998). Evidence from animal studies shows that an appropriate amount of Reelin is
necessary for proper neuronal migration (Fatemi et al., 1999; Goffinet, 1979), and a
reduced amount of Reelin results in cytoarchitectural alterations similar to what is seen in
schizophrenic patients (Fatemi, 2005). Additionally, the transcription factor Lhx6 is
reduced in post-mortem schizophrenia brains (Volk et al., 2012). Lhx6 is specific to cells
that are destined to be PV+ neurons and, during the prenatal period, it participates in the
regulation of cell type specification, tangential migration, and maturation of these
specific PV+ GABAergic neurons (Liodis et al., 2007; Volk et al., 2012; Zhao et al.,
2008). Reduced Lhx6 in schizophrenic patients might explain the failure of PV+ neurons
to appropriately express their phenotype. Changes in the expression of Reelin and Lhx6
in schizophrenia patients provide support for a developmental origin of the disorder.
Genetic factors may make the system more susceptible to stressors, but they do not
guarantee that one will inherit the disorder. Monozygotic twin studies indicate that there
is only a 40-48% chance of one twin being diagnosed with schizophrenia if the other is
already diagnosed (Suddath et al., 1990). These data indicate that although a genetic
disposition to the disorder exists, there are environmental risk factors that also contribute
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to the disease. Some environmental stressors that have been suggested to be involved in
changing the developmental trajectory include maternal stress and infection, prenatal
malnutrition, obstetric complications, and urban living (McNeil & Kaij, 1978; McNeil,
1987; Vassos et al., 2012). Several large epidemiological studies indicate that prenatal
exposure to viral infection increases the risk of schizophrenia due to the activation of the
maternal immune response (Adams et al., 1993; Izumoto, Inoue, & Yasuda, 1999;
Mednick, Huttunen, & Machon, 1994; Zuckerman et al., 2003). Stress in early life has
been shown to produce behavioral differences in adult individuals and is complemented
with data from rodent studies in laboratory settings (Gutman & Nemeroff, 2002).
Although these studies inflict stress upon the developing fetus, the mechanism by which
this would influence cytoarchitecture and molecular changes in the brain consistent with
schizophrenia is not known.
Development of the brain relies on the tightly regulated processes wherein the
coordinated activity of various mechanisms is essential. NMDA receptor-mediated
synaptic activity is necessary for normal development of various brain regions, as well as
for coordinated network activity due to their involvement in critical processes such as
establishing synaptic contacts, neuronal migration, and synaptogenesis (Contestabile,
2000; Komuro & Rakic, 1993; LoTurco et al., 1991). However, GABA signaling
precedes the development of NMDA receptor-mediated signaling and GABA plays a
pivotal role in normal brain development as well. In early brain development, GABA
acting on ionotropic GABAA receptors produces an excitatory, not inhibitory, response
both in vitro and in vivo (Ben-Ari, 2007; Leinekugel et al., 2002; Sipila et al., 2006). This
excitatory response is due to elevated intracellular chloride concentration in immature
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neurons that begins to reduce to what is normally seen in mature cells around PND 5-7 in
rodent pups and the effect of GABA acting on GABAA receptors becomes inhibitory
around PND 10 (Ben-Ari et al., 1989; Ben-Ari et al., 2007). The early excitation provided
by GABAA receptors aids in the membrane depolarization needed for NMDA receptors
to expel the Mg2+ ion in order for the channel to be functional (Ben-Ari et al., 2007; BenAri et al., 1997). Presynaptic GABAB receptors are functional at birth and provide
inhibitory control of neonatal network activity at this early stage in development (BenAri et al., 1997; McLean et al., 1996). Meanwhile, electrophysiological studies
demonstrate that postsynaptic GABAB receptors on either pyramidal cells or interneurons
are not functional during this time period (Caillard et al., 1998; Gaiarsa et al., 1995;
Nurse & Lacille, 1999; Verheugen, Fricker, & Miles, 1999). Embryonic and neonatal rat
hippocampal and cortical neurons do not exhibit postsynaptic GABAB receptor-mediated
responses (the activation of potassium and the inhibition of Ca2+ currents) until after PND
7 (Ben-Ari et al., 1997) due to the lack of coupling between the receptors and the ion
channels (via G-proteins) (Fukuda, Mody, & Princa, 1993). The balance between
excitation and inhibition during early brain development is vital for normal neuronal
network formation.
Since NMDA receptor activation is vitally important in development, and postmortem analyses point to alterations during critical periods associated with
schizophrenia, studies have combined these theories by administering NMDA receptor
antagonists to rodent pups during development to evaluate if deficits consistent with
schizophrenia are produced. The first two weeks of life for a rat pup (especially at PND
day 7) are a vulnerable period of brain development that correlates with the second
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trimester of pregnancy in humans (See Figure 1 below; Bayer et al., 1993; Clancy,
Darlington, & Finlay, 2001; Clancy et al., 2007). Studies have found that administering
NMDA receptor antagonists (PCP, MK-801, and few using ketamine) during early stages
of brain development in rodents (PND 7-14) results in an increase of neurodegeneration
in brain areas implicated in schizophrenia and that this neurodegeneration is consistent
with normal apoptosis that occurs during development and, therefore, is not related to
excitotoxicity (Ikonomidou et al., 1999; Wang et al., 2001; Wang & Johnson, 2005). As
mentioned, neurodegeneration and excitotoxic effects are not seen in post-mortem
analyses of schizophrenic patients. Additionally, studies have found behavioral deficits in
adult rats that had previously been administered NMDA receptor antagonists during the
first weeks of postnatal life (see Figure 1 below). These studies demonstrate deficits in
sensorimotor gating and PPI, consistent with schizophrenia-like symptoms (Abekawa et
al., 2011; Anastasio & Johnson, 2008; Beninger et al., 2002; Broberg et al., 2010; Harris
et al., 2003; Rasmussen et al., 2007; Turner et al., 2010; Van den Buuse, Garner, & Koch,
2003; Wang et al., 2001; Wang & Johnson, 2005), with few using other behavioral tasks
(Andersen & Pouzet, 2004). However, these previous studies use a moderate to high dose
of drug that could possibly mimic a very large shutdown of the NMDA receptor system.
It would be interesting to see if the effect of NMDA receptor antagonists administered at
low doses produces similar learning and memory deficits in adulthood.
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Figure 1. A comparison of rat and human brain development with a timeline of methods
used in developmental approaches to schizophrenia. Derived from Tseng et al., 2009.
The use of ketamine compared to other NMDA receptor antagonists in schizophrenia
research has advantages. It is commonly used in veterinary medicine (and to some extent,
pediatrics) as a dissociative anesthetic; however, at subanesthetic doses, it displays
different properties. Compared to the other NMDA receptor antagonists, ketamine has a
lower potency, a shorter duration of action, a faster rate of induction, and is effective
across different animal species (Hevers et al., 2008). In our laboratory, the administration
of ketamine in adult systems has proven to model deficits seen in schizophrenia for
several behavioral tasks such as PPI, the Morris water maze, and trace CCF (Bolton et al.,
2012; Sabbagh et al., 2012). These features allow researchers to have better control of the
drug in vivo, making it the optimal choice as an NMDA receptor antagonist. However, its
utility at low doses in development to model deficits seen in schizophrenia has yet to be
elucidated.
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A more puzzling question in schizophrenia research is the effects of
pharmacologically altering the GABAB receptor system in development. There has not
yet been a study that examines administration of a GABAB receptor antagonist or agonist
during development. Since NMDA receptors are centrally involved in the developmental
pathogenesis of schizophrenia and rely on GABAB receptors during development, it is
unknown what may occur if the GABAB receptor system is altered during this stage. As
previously discussed, GABABR1 knockout mice display massive behavioral impairments,
die prematurely, and may be a better model for epilepsy than schizophrenia (Prosser et
al., 2001; Schuler et al., 2001). However, disturbing the GABAB receptors either by
enhancing or inhibiting their function intermittingly could provide valuable insight into
their role as it relates to this disorder.
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Hypotheses and Implications
Building upon the wealth of research that implicates altered function of the
NMDA receptor and changes in GABAergic signaling in schizophrenia as well as the
importance of their role in brain development, we examined the behavioral and
biochemical consequences of disrupting the functioning of either NMDA or GABAB
receptors during critical time points in development.
Hypothesis 1:
We administered the NMDA receptor antagonist ketamine at a low dose (8
mg/kg) to rat pups at PND 7, 9, and 12. In adulthood, the animals should exhibit
sensorimotor gating deficits measured by a reduction in PPI, impairments in
spatial learning and memory demonstrated by the Morris water maze task, and
deficits in fear associative learning seen in trace CCF compared to controls. The
examination of brain tissue should result in alterations of proteins associated with
NMDA receptors, GABA receptors, and GAD67, all of which have been found to
be disrupted in schizophrenia.
Implications of Hypothesis 1:
If the low dose ketamine administration during development produces
behavioral and protein expression changes consistent with what is
observed in other schizophrenia models, then the data would indicate that
alterations in NMDA receptors at the specific time points (PND 7, 9, and
12) induce a change in the system that results in deficits consistent with
the disorder. Alternatively, if the dose and schedule of ketamine
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administration does not induce the proposed deficits, it may be possible
that a subtle, transient blockade of this receptor system is not enough to
disrupt the developing network system and an increase in dose or multiple
injection days may be considered.
Hypothesis 2:
In addition to the administration of ketamine to post-natal rat pups, we
administered the GABAB receptor antagonist phaclofen and the GABAB receptor
agonist baclofen to different groups of animals. The injections were on PND 7, 9,
and 12 to determine if a change in GABAergic signaling during critical periods
produces changes in behavior. There is a delicate balance in GABA signaling
during development (as previously demonstrated) so the present study will
determine if blocking or enhancing GABAB receptor function during this
developmental period alters behavior in adulthood. We hypothesized that
phaclofen and baclofen, each, would produce behavioral deficits (reductions in
PPI and deficits in the Morris water maze and trace CCF) similar to ketamine
deficits in Hypothesis 1. Blocking (with phaclofen) or enhancing (with baclofen)
theoretically would alter connections in the developing brain and change network
function. We also proposed that the tissue analyses would indicate alterations in
proteins related to the GABAergic signaling.
Implications of Hypothesis 2:
If altering GABAB receptors, either by reducing or enhancing their
function, during early brain development produces behavioral and/or
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protein changes similar to what is seen in schizophrenia, then this
experiment will provide evidence for the involvement of GABA signaling
dysfunction potentially being involved in the disorder. If no deficits are
detected with either phaclofen or baclofen, then alternate dosages and
schedule of administration would be useful. The possibility exists that
direct alterations of GABAB receptor function alone may be insufficient to
alter developmental trajectories.
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CHAPTER 3
MATERIALS AND METHODS
Subjects
Eight timed pregnant Sprague-Dawley dams were obtained from Charles River
Laboratories (Hollister, CA). Dams were individually housed until parturition with a 12
hour light/dark cycle and with food and water available ad libitum. The day of birth was
considered PND 0. Pups were sexed and randomly assigned to one of four treatment
groups (saline, ketamine, baclofen, or phaclofen) on PND 2. All pups were weaned on
PND 21 and pair housed throughout the remainder of the experiment with male (n = 55)
and female (n = 35) animals housed in separate colony rooms. Behavioral testing began
on PND 60 which corresponds to brain maturity in early adulthood for humans (Pignatelli
et al., 2006). All procedures were performed in accordance with NIH guidelines for
ethical treatment of research subjects, and approved by the University of Nevada, Las
Vegas Animal Care and Use Committee.
Drug Treatments
All drugs were mixed with physiological saline (0.9% NaCl) to achieve a final
concentration of 8 mg/ml ketamine (ketamine HCL from Henry-Schein, Indianapolis,
IN), 2 mg/ml baclofen (baclofen hydrochloride from Sigma-Aldrich, St. Louis, MO), 0.3
mg/ml phaclofen (from Sigma-Aldrich, St. Louis, MO). The drugs were administered
subcutaneously (SC) at a dose of 1 ml/kg. Animals were randomly assigned one of the
three treatment groups: saline (n = 14 males; n = 6 females), ketamine (n = 14 males, n =
10 females), baclofen (n = 14 males; n = 9 females), and phaclofen (n = 13 males; n = 10
females).
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Apparatus
Prepulse Inhibition of Acoustic Startle
Acoustic startle chambers (San Diego Instruments, San Diego, CA) measuring 28
cm (W) x 28 cm (H) x 28 cm (L) were used for the acoustic startle and PPI. Inside the
chamber, the animals were individually placed in a transparent Plexiglas tube (10 cm
wide and 20 cm long) that is mounted on an accelerometer which measures changes in
movement. A Cobalt Instruments computer using Acoustic Startle software package
(Startle, San Diego Instruments) recorded the data from the accelerometer.
Fear Conditioning Chambers
A Freeze Monitor chamber (San Diego Instruments) measuring 25.4 cm (W) x
19.05 cm (H) x 25.4 cm (L) with a stainless steel grid floor and Plexiglas walls was used
to perform both the fear conditioning training and contextual fear test. The chamber was
cleaned with Formula 409 (Chlorox, Oakland, CA) solution at the end of each session.
An altered context chamber was used to test cued fear. This chamber consisted of an
opaque plastic enclosure measuring 12.7 cm (W) x 26.67 cm (H) x 43.18 cm (L) with the
addition of a vanilla scent on an inner wall to ensure a different olfactory background for
the altered context. A solution of 0.1% ethanol was used to clean the chamber after each
session. The chambers were connected to a Cobalt Instruments computer with the Freeze
Monitor software (San Diego Instruments) to run each session. Freezing behavior (no
movement besides breathing) was recorded every 10 seconds.
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Morris Water Maze
The Morris water maze procedure was performed in a white polyethylene circular
tank, 1.8 m (diameter), 76 cm (H), and 4.7 mm in thickness (San Diego Instruments). The
tank was filled with tap water 48 cm deep and maintained at 25˚C. The addition of nontoxic paint made the water opaque to conceal the hidden platform (10 cm x 10 cm square
platform made of clear plastic). The tank was divided into four quadrants, one in which
the hidden platform was placed in the center 30 cm from inside the wall of the tank and
1.5 cm below the surface of the water. A 13 cm x 13 cm square white plastic cover,
protruding 3 cm above the water, was placed on top of the platform during the visible
training trials. The tank was positioned in the center of a training room (separate from the
colony room) with large geometric shapes positioned on all four walls to serve as distal
spatial cues for the animals to find the hidden platform. Trials were recorded and
captured using a video tracking system (Smart, San Diego Instruments) from a Sony
Handycam camera connected to a Cobalt Instruments computer. Latency to locate the
hidden platform, speed of swimming, and thigmotaxis (proportion of time spend along
the outer edge of the maze) data was collected for each trial. The amount of time subjects
spent in each quadrant was recorded for the probe trial.
Tail Flick
The tail flick procedure was performed using a circular glass bowl, 20.32 cm
(diameter) and 7.62 cm (H), filled with 1800 ml of water. The bowl was placed on a
heating plate to maintain the water at 55˚C throughout each session.
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Drug Administration
After the pups were sexed and randomly assigned to treatment groups on PND 2,
they received 1 ml/kg subcutaneous injection of saline, ketamine, baclofen, or phaclofen
on PND 7, 9, and 12 (Figure 1) then weighed every day until weaning (PND 21) to
ensure proper growth and development.
Behavioral Testing
All behavioral testing began once animals reached PND 60 to ensure they reached
early adulthood. All experimenters were blind to the subject’s treatment group throughout
testing.
Prepulse Inhibition of Acoustic Startle
Animals were taken into a separate training room and individually placed in the
startle chambers. Animals were given five minutes to acclimate to the environment and
presented with background noise (65 dB) throughout the session. Acoustic startle
responses were examined after the presentation of 30 ms noise bursts of 90, 100, 110, and
120 dB. Sensorimotor gating was tested with auditory white noise prepulses of 74, 82, 86,
or 90 dB presented 40 ms or 100 ms prior to the 120 dB startle pulse. Inter-trial intervals
were randomized between 10 and 55 seconds. For each session, a random order of trial
type presentations was presented 5 times. When evaluating the acoustic startle data, the
first trial of each acoustic startle intensity response was discarded and averages of the
remaining four trials were used for calculation. Percent PPI was calculated using the
following equation: 100-[(average startle response with pre-pulse)/(average acoustic
startle)]*100.
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Cued and Contextual Fear Conditioning (CCF)
Subjects were individually taken from the colony room and placed in the fear
conditioning chamber located in a separate training room. The animals were allowed to
freely explore the chamber during the initial two minutes of the training session in which
no stimuli were presented. Following the initial two minutes in the chamber, a 2.9 kHz 88
dB tone conditioned stimulus (CS) was presented for 30 s; 2.5 s following the termination
of the CS, a 1 second 0.5 mA footshock (US) was administered. Following the
termination of the US, a two minute interval elapsed prior to the next CS and US
presentation. A total of 4 CS-US pairings were presented in the training session, each
separated by two minute intervals. After the completion of the last pairing, the animals’
behavior was observed for a final two minutes. The animals’ freezing behavior was
evaluated every ten seconds throughout the session by a trained experimenter blind to the
experimental group. The criterion for freezing consisted of no movement of the animal
other than breathing. Freezing behavior was recorded during the training session for the
first two minutes (pre-training freezing) and for the final two minutes (post-training).
Once the session was complete, the animal was returned to its home cage in the colony
room and the chamber was cleaned.
Cued fear testing (fear to the CS) was examined 24 hours after training. Animals
were individually placed in the altered context for a total of 13 minutes. The session
consisted of an initial two minute interval, during which no stimuli were presented in
order to evaluate freezing to the novel environment. A one minute presentation of the
original CS used in training was presented, followed by a two minute interval between
the onsets of the next CS tone, for a total of 4 CS tone presentations. Freezing behavior
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was measured throughout the entire session. The animals were brought back to their
home cage following the completion of the session and the chamber was thoroughly
cleaned with 0.1% ethanol.
Contextual fear (fear to the training environment) was tested 48 hours after
training. Animals were placed in the initial training chamber and allowed to freely
explore for 10 minutes without any CS or US presentations. Freezing behavior was
measured during the entire session in five, 2 minute bins. After the session, the animals
were returned to their home cage and the chamber was cleaned.
A cued fear session (72 hours after training) and contextual fear session (96 hours
after training) were administered in an identical fashion as previously described
following the 48 hour contextual test. However, following the 96 hour contextual fear
session, one CS-US pairing was presented (reminder trial) followed by a final two minute
period of observation. An additional cued fear session (24 hours after reminder) and
contextual fear session (48 hours after reminder) was carried out on subsequent days
using the same protocols detailed above.
Morris Water Maze
Individually, animals were taken from the colony room into a separate testing
room. A computer desk, a table with a heating cage, large geometric shapes on each wall,
and the experimenter served as distal spatial cues as they can be seen from inside the
maze. The animal was placed into the maze and into the water along the outer wall of one
of the three randomly chosen quadrants that do not contain the hidden platform. The
animal was allowed to swim until locating the hidden platform or for a maximum of 60
seconds. After 60 seconds, the experimenter guided the animal to the hidden platform.
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Each animal was given 20 seconds to sit/stand on the platform to allow spatial orientation
to distal extra-maze cues after which they were taken out of the maze and placed in a
holding cage under a heat lamp for 30 seconds. Three additional trials were conducted
using the same protocol for a total of four training trials per day. After the fourth interval
under the heating lamp, the animal was gently dried with a towel and taken back to its
home cage. The platform remained in the same location for each trial and across days.
Training trials were conducted on successive days until the completion of either six days
of hidden platform training or until the controls reached a latency of ≤ 15 seconds. The
animals’ path, latency, thigmotaxis, swim speed, and quadrant location was recorded.
Once the control animals reached the hidden platform latency criterion, a single
probe trial was performed the following day. The hidden platform was removed from the
maze and the animal was allowed to swim for 60 seconds with the tracking system
measuring the amount of time the animal spent in each quadrant. To examine the ability
of how well the animals learn a new location of the hidden platform, a reversal procedure
was used in which the platform was moved to the opposite quadrant (180 degrees from
original location) and the animals were given four trials with the same protocol as a
hidden platform day. To test for visual and motor capabilities, a non-spatial test was
performed using a visible platform. This task is similar to the hidden platform protocol
except that the platform is visible to the animal and moved on successive trials to
different quadrants for each trial.
Tail Flick
In order to ensure any differences that may be observed during the fear
conditioning procedure are not tied to changes in nociception (i.e. analgesia), a standard
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tail flick nociception test was performed on all animals. Subjects were individually taken
from their home cage into a testing room. The initial 2–3 centimeters of the tip of the tail
was placed in 55º C water and the latency for the animal to flick its tail out of the water
was recorded. A maximum of 10 seconds was set as a criterion for withdrawal (flick).
Tissue Analysis
Tissue Collection
Following the tail flick test, all animals were humanely euthanized using CO2
asphyxiation. Brains were immediately removed following CO2 asphyxiation. The frontal
portion of the cortex was dissected out, placed in microcentrifuge tubes, and kept frozen
at -80˚C until tissue homogenization.
SDS-PAGE Western Blotting
Prefrontal cortices were homogenized using a RIPA buffer (20 mM pH 7.5 TrisHCL, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% sodium deoxycholate, 2.5 mM
sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin;
Cell Signaling, Danvers, MA) with 1 mM DTT, 1 mM PMSF, 20µg/ml aprotinin, and
0.1% SDS added. Homogenization was performed using a handheld Polytron
(Kinematica Inc., Luzern, Switzerland) tissue homogenizer. Homogenized tissue was
centrifuged for 15 minutes at 15,000 x g at 4˚C. Supernatant was removed without
disturbing the pellet and a protein concentration assay was performed using the
bicinchoninic acid assay (BCA, Pierce, Rockford, IL).
Protein samples were loaded into 10% acryl gels at a concentration of 2 µg/µl
with a mixture of Laemmeli buffer containing 2% SDS (BioRad, Hercules, CA) and DI
water for a total of 10 µL volume. SDS-PAGE was held at a constant current 0.04 A for
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45 minutes to separate protein samples according to molecular weight. Following the
separation, the proteins were electrotransferred at 0.25 A for 1 hour to 0.2 µm
nitrocellulose membranes (GE Water and Process Technologies, Feasterville-Trevose,
PA). Membranes were placed in a blocking buffer with 5% BSA and TBST (1x Trisbuffered saline with 0.05% Tween 20) before being incubated overnight at 4˚C in
primary antibody (anti-GABAAα5 polyclonal rabbit, 1:750 (Millipore, Billerica, MA);
anti-GABAB1 polyclonal rabbit, 1:2000 (Cell Signaling Technology, Danvers, MA); antiGABAB2 polyclonal rabbit, 1:1000 (Cell Signaling Technology); anti-GAT1 polyclonal
rabbit 1:1000 (Cell Signaling Technology); anti-NR2B polycolonal rabbit 1:100 (Cell
Signaling Technology); anti-Kalirin polyclonal rabbit, 1:1000 (Cell Signaling
Technology); anti-β-Actin monoclonal rabbit, 1:20,000 (ProteinTech, Chicago, IL)).
Membranes were returned to room temperature the following day and washed with TBST
3 times for 10 minutes each. Following washes, membranes were incubated in secondary
antibody (HRP-conjugated anti-rabbit, 1:5000, Vector Laboratories, Burlingame, CA) for
1.5 hours at room temperature. Following 3 additional 10 minute washes with TBST, the
membranes were exposed to Amersham ECL Plus detection system (GE Healthcare Life
Sciences, Pittsburgh, PA) and imaged using a Typhoon 9410 Variable Mode Imager (GE
Healthcare Life Sciences). ImageQuant 5.2 software (GE Healthcare Life Sciences) was
used to determine protein quantities. The proteins of interest were normalized to β-Actin
density. The treatment group’s normalized values were compared to the average control
(saline) normalized values for each membrane. All SDS-PAGE experiments were all run
in duplicate to ensure consistent data.

38

Statistical Analysis
Acoustic startle response and PPI data were analyzed via repeated measures
analysis of variance (RM-ANOVA) across startle or prepulse intensities. One-way
ANOVA for individual startle and prepulse intensities were performed after a significant
RM-ANOVA. Mean latencies, swim speed, and thigmotaxis from the water maze for
hidden platform days were analyzed across days using RM-ANOVA. Data from the time
spent in each quadrant during the probe trial in the water maze were analyzed using oneway ANOVA (target versus other quadrants). RM-ANOVA were used for the CCF data
except one-way ANOVA were used to determine differences between treatment groups
in pre CS-US freezing and post CS-US freezing on the training day. Mean latencies for
tail flick and mean densities for western blotting were analyzed using one-way ANOVA.
Tukey post-hocs were performed following a significant ANOVA. To parse out the
differences between the control group and either ketamine or the GABAB ligands,
separate analyses were conducted. Males and females were analyzed separately except
when comparing males versus females for the GAD67 protein.

39

CHAPTER 4
RESULTS
Behavioral Testing
Prepulse Inhibition of Acoustic Startle
A significant difference was observed in acoustic startle response (Figure 2)
between treatment groups for the male animals (RM-ANOVA; F(3,216) = 3.425, p =
0.018). The baclofen group exhibited a significant increase in startle response compared
to saline (Tukey post hoc; p = 0.013). Analysis of individual startle intensities revealed
that the significant increase in acoustic startle for the baclofen group occurred at 100 dB
(One-way ANOVA; F(3,216) = 5.212, p = 0.002; Tukey post hoc: baclofen versus saline, p
= 0.020) and 110 dB (One-way ANOVA; F(3,216) = 4.842, p = 0.003; Tukey post hoc:
baclofen versus saline, p = 0.002) but not at 120 dB compared to saline. Conversely,
significant reductions in startle responses were observed between the female treatment
groups compared to saline (RM-ANOVA; F(3,136) = 6.942, p = 0.000). The baclofen and
phaclofen treated groups displayed a significant decrease in acoustic startle response
compared to saline (Tukey post hoc: baclofen versus saline, p 0.019; phaclofen versus
saline, p = 0.009). The decrease in acoustic startle response occurred at the 120 dB
intensity (One-way ANOVA; F(3,136) = 5.920, p = 0.001; Tukey post hoc: baclofen versus
saline, p = 0.010; phaclofen versus saline, p = 0.004).
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Figure 2. Acoustic Startle Responses. Mean startle amplitudes (±SEM) in response to
noise bursts at multiple decibel intensities for males and females. Baclofen treated males
exhibited a significant increase in startle response while the baclofen and phaclofen
treated females displayed a significant reduced startle response. * = Significantly
different from saline, p < 0.05.
For the PPI trials with a 100 ms inter-stimulus interval (ISI; Figure 3), no
significant differences were observed between treatment groups compared to controls for
the male animals across all prepulse intensities (RM-ANOVA; F(3,216) = 2.268, p =
0.082). However, the female animals displayed a significant difference between treatment
groups compared to controls (RM-ANOVA; F(3,136) = 8.586, p = 0.000). Across prepulse
intensities, the female baclofen group (Tukey post hoc, p = 0.006) and phaclofen group
(Tukey post hoc, p = 0.000) exhibited a significant reduction in PPI. These reductions
were observed at all of the prepulse intensities except for the 86 dB prepulse (One-way
ANOVA; 74 dB: F(3,136) = 4.058, p = 0.008, Tukey post hoc: baclofen versus saline, p =
0.018, phaclofen versus saline, p = 0.010; 78 dB: F(3,136) = 5.066, p = 0.002, Tukey post
hoc: balcofen versus saline, p = 0.015; phaclofen versus saline, p = 0.020; 82 dB: F(3,136)
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= 4.354, p = 0.006, Tukey post hoc: phaclofen versus saline, p = 0.004; 90 dB: F(3,136) =
3.571, p = 0.016, Tukey post hoc: phaclofen versus saline, p = 0.018)..
Separate analyses were conducted to compare only the ketamine and saline
groups for the PPI trials with 100 ms ISI (Figure 3). A significant reduction in PPI was
observed between the ketamine treated female group versus the female controls across
prepulse intensities (RM-ANOVA; F(1,62) = 8.313, p = 0.005), significant reductions were
observed at the 74 (One-way ANOVA; F(1,62) = 7.525, p = 0.008) and 86 dB (F(1,62) =
4.247, p = 0.044) prepulse intensities.
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Figure 3. Percent Prepulse Inhibition with 100 ms ISI. Mean percent PPI (±SEM) at
multiple prepulse intensities preceding 120 dB startle stimulus. No differences observed
between the male treatment groups while significant reductions in PPI were seen for the
baclofen and phaclofen treated females. # = Significantly differently from saline
(ketamine analyzed in isolation), p < 0.05. * = Significantly different from saline, p <
0.05.

An evaluation of the PPI trials with a 40 ms ISI (Figure 4) revealed a significant
difference between treatment groups across prepulse intensities in the male animals (RMANOVA; F(3,161) = 3.931, p = 0.010). Post-hoc analyses revealed a significant reduction
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in PPI in the phaclofen group (Tukey post hoc: phaclofen versus saline, p = 0.024). Oneway ANOVA for each prepulse intensity revealed a significant reduction only at the 74
dB prepulse (F(3,161) = 2.930, p = 0.035; Tukey post hoc: phaclofen versus saline, p =
0.039). Female animals demonstrated a similar significant reduction in PPI across
prepulse intensities (F(3,101) = 9.843, p = 0.000) for the phaclofen group compared to
saline (Tukey post hoc: p = 0.000). One-way ANOVA for individual prepulse intensities
revealed the same significant reduction at the 74 dB prepulse intensity (F(3,101) = 5.439, p
= 0.002; Tukey post hoc: phaclofen versus saline, p = 0.006), 86 (F(3,101) = 4.322, p =
0.007; Tukey post hoc: phaclofen versus saline, p = 0.010), as well as a significant
difference at the 90 dB prepulse (F(3,101) = 3.145, p = 0.028; Tukey post hoc: phaclofen
versus saline, p = 0.045).
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Figure 4. Percent Prepulse Inhibition with 40 ms ISI. Mean percent PPI (±SEM) at
multiple prepulse intensities preceding 120 dB startle stimulus. Significant reductions in
PPI were observed across prepulse intensities for both male and female phaclofen treated
groups with a lack of PPI occurring at the 74 dB. * = Significantly different from saline,
p < 0.05.
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Cued and Contextual Fear Conditioning
No significant differences were observed in the freezing behavior of the males
throughout training on Day 1 (see Figure 5). All groups froze equivalently during the two
minute interval before the onset of the CS-US pairings (Pre CS-US; F(3,51) = 0.709, p =
0.551) and during the two minute interval after the last CS-US pairings (Post CS-US;
F(3,51) = 0.696, p = 0.559). Similarly, the female animals were equivalent in their freezing
behavior between groups during the Pre CS-US (F(3,31) = 0.908, p = 0.448) and Post CS-

Proportion of Time Freezing

US (F(3,31) = 0.536, p = 0.661) as shown in Figure 5.
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Figure 5. Day 1 CCF Training. Proportion of time freezing (±SEM) was determined for
the first two minutes of training (Pre CS-US) and the last two minutes of training (Post
CS-US) for the males and females. No differences were observed between treatment
groups.
Following training, fear to the CS in a novel environment (cued fear) was tested
(Cued Fear Day 2; Figure 6a). No differences were observed between the male treatment
groups in freezing behavior during the first two minutes of the cued fear session (Pre
CS1; F(3,51) = 0.985, p = 0.407) and during the presentation of the cues (RM-ANOVA
across CS1-CS4; F(3,51) = 0.767, p = 0.518). The female animals also displayed no
differences in freezing between treatment groups during Pre CS1 (F(3,31) = 2.847, p =
0.054) and similar freezing behavior during cue presentations (RM-ANOVA across CS1CS4; F(3,31) = 1.897, p = 0.151).
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Freezing to the training environment on (contextual fear) on Day 3 (Figure 6b)
revealed no differences between the male treatment groups across the entire session (RMANOVA across Blocks 1-5; F(3,51) = 0.204, p = 0.893) and, consistent with the males, no
differences were observed for the female animals (RM-ANOVA across Blocks 1-5;
F(3,31) = 2.626, p = 0.068).
For Cued Fear Day 4 (Figure 7a), no significant differences were observed in
freezing behavior between male treatment groups for Pre CS1 (F(3,51) = 0.885, p = 0.455)
or across cue presentations (RM-ANOVA across CS1-CS4; F(3,51) = 0.348, p = 0.791).
Female animals also displayed no significant differences between treatment groups for
freezing behavior during Pre CS1 (F(3,31) = 0.670, p = 0.577) and across cue
presentations(RM-ANOVA across CS1-CS4; F(3,31) = 0.989, p – 0.411).

45

(a)
Proportion of Time Freezing

0.9
0.8
0.7
Saline

0.6
0.5

Ketamine

0.4

Baclofen

0.3

Phaclofen

0.2
0.1
0

Pre CS1

CS1

CS2

CS3

CS4

Pre CS1

Males

Proportion of Time Freezing

(b)

CS1

CS2

CS3

CS4

Females
Portion of Session

0.7
0.6

Saline
0.5

Ketamine

0.4

Baclofen

0.3

Phaclofen

0.2
0.1
0

Block 1 Block 2 Block 3 Block 4 Block 5
Males

Block 1 Block 2 Block 3 Block 4 Block 5

Portion of Session (2 min each block)

Females

Figure 6. Cued Fear Day 2 and Contextual Fear Day 3. Proportion time freezing (±SEM)
was measured for Cued Fear Day 2 (a) during the first two minutes before the
presentation of the cues (Pre CS1) and during the cue presentations (CS1-CS4) and for
Contextual Fear Day 3 (b) during each 5 two minute blocks. No significant differences
were observed between treatment groups.
No differences in freezing were detected on Contextual Fear Day 5 (Figure 7b)
between the male treatment groups (RM-ANOVA across Blocks 1-5; F(3,51) = 0.282, p =
0.838) and female treatment groups (RM-ANOVA across Blocks 1-5; F(3,31) = 2.571, p =
0.072) across the entire session. A single reminder trial (CS-US) was presented at the end
of the session. During the two-minute interval following the reminder trial, neither male
(F(3,51) = 1.031, p = 0.387) nor female (F(3,31) = 0.369, p = 0.776) animals displayed
differences in freezing behavior.
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Figure 7. Cued Fear Day 4 and Contextual Fear Day 5. Proportion time freezing (±SEM)
was measured for Cued Fear Day 4 (a) during the first two minutes before the
presentation of the cues (Pre CS1) and during the cue presentations (CS1-CS4) and for
Contextual Fear Day 5 (b) during each 5 two minute blocks. Freezing was measured
during the cue presentation (Reminder) and the final two minutes after the CS-US
presentation (Post Reminder).
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Figure 8. Cued Fear Day 6 and Contextual Fear Day 7. Proportion time freezing (±SEM)
was measured for Cued Fear Day 6 (a) during the first two minutes before the
presentation of the cues (Pre CS1) and during the cue presentations (CS1-CS4). The
phaclofen treated females displayed a significant decrease in freezing during the CS
presentations. Proportion time freezing (±SEM) was measured for Contextual Fear Day 7
(b) during each 5 two minute blocks. No differences between treatment groups were
observed. * = Significantly different from saline, p < 0.05.
Freezing behavior on Cued Fear Day 6 Post Reminder (Figure 8a) revealed no
significant differences between treatment groups for the male animals for Pre CS1 (F(3,51)
= 1.989, p = 0.127) and across cue presentations (RM-ANOVA across CS1-CS4; F(3,51) =
1.263, p = 0.297). Although no significant differences among treatment groups in
freezing behavior were seen for Pre CS1 for female animals (F(3,31) = 1.273, p = 0.301),
the phaclofen group displayed a significant decrease in freezing across cue presentations
(RM-ANOVA; F(3,31) = 3.012, p = 0.045; Tukey post hoc: phaclofen versus saline, p =
0.028). One-way ANOVA revealed the significant reductions occurred during CS1 (F(3,31)
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= 4.298, p = 0.012; Tukey post hoc: phaclofen versus saline, p = 0.006) and CS2 (F(3,31) =
3.308, p = 0.033; Tukey post hoc: phaclofen versus saline, p = 0.026).
For Contextual Day 7 Post Reminder (Figure 8b), no significant differences were
found for the male animals across the two minute blocks (RM-ANOVA across blocks;
F(3,51) = 0.386, p = 0.764). Similarly, no significant differences in freezing were observed
between treatment groups for the female animals (RM-ANOVA across blocks; F(3,31) =
1.811, p = 0.166).

49

Morris Water Maze
Latency to reach the hidden platform across successive days was measured for six
consecutive days (Figure 9a). No significant differences were observed in latency for
males between treatment groups across hidden platform training (RM-ANOVA; F(3,215) =
2.079, p = 0.104). Similarly, latencies between treatment groups for the female animals
were not significantly different across days (RM-ANOVA; F(3,215) = 0.017, p = 0.997).
Swim speed across hidden platform training days (Figure 10a) revealed no differences
between the male treatment groups (RM-ANOVA; F(3,215) = 1.989, p = 0.117) and the
female treatment groups (RM-ANOVA; F(3,79)

= 1.711, p = 0.172). However,

thigmotaxis (proportion of time spent on the outer perimeter, Figure 10b) differed among
the male treatment groups across hidden platform days (RM-ANOVA; F(3,215) = 2.882, p
= 0.037) with the ketamine group spending significantly more time along the perimeter
(Tukey post hoc, p = 0.049). The female treatment groups displayed no differences in
time spent along the perimeter across hidden platform days (RM-ANOVA; F(3,80) =
2.342, p = 0.079). Separate analyses were performed comparing only male ketamine
group to the male saline group. The male ketamine group displayed a significantly
increased latency to find the hidden platform over successive days (RM-ANOVA; F(1,38)
= 6.883, p = 0.012). Swim speed was not significantly different between the male saline
and ketamine groups (RM-ANOVA; F(1,109) = 0.063, p = 0.802), the ketamine group did
display higher thigmotaxis (RM-ANOVA; F(1,109) = 7.141, p = 0.009) which could be
related to the longer latency during the hidden trials.
After completion of the last day of hidden platform training, a probe trial was
performed (Figure 9b). The baclofen treated males failed to display a selective search as
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measured by time spent in target quadrant versus all other quadrants (F(3,51) = 4.493, p =
0.007; Tukey post hoc: target versus quadrant 1, p = 0.118; target versus quadrant 2, p =
0.043; target versus quadrant 3, p = 0.006 ). The male saline, ketamine, and phaclofen
group each displayed a significant search during the probe trial (saline: F(3,55) = 15.015, p
= 0.000; Tukey post hoc, target versus quadrant 1, p = 0.000; target versus quadrant 2, p
= 0.000; target versus quadrant 3, p = 0.000; ketamine: F(3,55) = 13.886, p = 0.000; Tukey
post hoc, target versus quadrant 1, p = 0.008; target versus quadrant 2, p = 0.000; target
versus quadrant 3, p = 0.000; phaclofen: F(3,51) = 11.176, p = 0.000; Tukey post hoc,
target versus quadrant 1, p = 0.005; target versus quadrant 2, p = 0.000; target versus
quadrant 3, p = 0.000). In the female animals, a selective search for the former platform
location was observed for the baclofen (F(3,32) = 15.153, p = 0.000; Tukey post hoc target
versus quadrant 1, p = 0.000; target versus quadrant 2, p = 0.000; target versus quadrant
3, p = 0.000) and phaclofen (F(3,36) = 4.865, p = 0.006; Tukey post hoc target versus
quadrant 1, p = 0.039; target versus quadrant 2, p = 0.008; target versus quadrant 3, p =
0.027) treated female groups as measured by the proportion of time spent in the target
quadrant. The female saline and ketamine treatment groups did not exhibit a selective
search, failing to spend significantly more time in any quadrant (saline: F(3,20) = 1.362, p =
0.283; ketamine: F(3,36) = 1.466, p = 0.240).
Reversal training was carried out 24 hours following the probe trial. Neither the
males nor female animals displayed any significant differences in latency to find the new
platform location (Figure 9a; Males: F(3,215) = 1.079, p = 0.359; Females: F(3,136) = 0.767,
p = 0.514) or swim speed differences (Figure 10a; Males: F(3,215) = 0.734, p = 0.533;
Females: F(3,135) = 1.740, p = 0.162). However, the ketamine treated male group exhibited
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a significant increase in thigmotaxis compared to the control group (Figure 10b; F(3,215) =
4.621, p = 0.04; Tukey post hoc saline versus ketamine, p = 0.010). No significant
differences in thigmotaxis were observed between the female treatment groups (Figure
10b; F(3,136) = 1.527, p = 0.210).
Visible platform training was conducted to assess visuomotor abilities. Significant
differences were found among the male treatment groups for latency to locate the visible
platform (Figure 9a; RM-ANOVA; F(3,215) = 3.039, p = 0.030); however, no significant
differences between groups were detected in post hoc analyses (Tukey post hoc; saline
versus ketamine, p = 0.927; saline versus baclofen, p = 0.991; saline versus phaclofen, p
= 0.069). While no differences were observed between the male treatment groups for
swim speed (Figure 10a; RM-ANOVA; F(3,215) = 0.817, p = 0.457), the ketamine and
phaclofen groups displayed an increase thigmotaxis across the two visible days (Figure
10b; RM-ANOVA; F(3,215) = 6.061, p = 0.001; Tukey post hoc, saline versus ketamine, p
= 0.001; saline versus phaclofen, p = 0.028). Based on the females’ performance during
the hidden platform and reversal training days, they received only one day of visible
training. No significant differences were observed for the latency (Figure 9a; F(3,136) =
0.086, p = 0.968) and swim speed (Figure 10a; F(3,136) = 2.424, p = 0.069) between
treatment groups; however, the ketamine treated female group displayed an increased
thigmotaxis compared to saline (Figure 10b; F(3,136) = 3.165, p = 0.027; Tukey post hoc
saline versus ketamine, p = 0.025).
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Figure 9. Morris Water Maze Latency and Probe Trial. (a) Mean latency (±SEM) across
hidden platform days, reversal, and visible. Male ketamine group took significantly
longer to find hidden platform across days. No differences were observed in the females.
* = Significant difference between saline versus ketamine, p < 0.05. (b) Mean percent
time in quadrant (±SEM) with target versus quadrants for each treatment group. Male
saline, ketamine, and phaclofen groups and female baclofen and phaclofen group spent
significantly more time in the target quadrant versus quadrant 1, 2, and 3. * =
Significantly different from target quadrant, p < 0.05.
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Figure 10. Swim Speed and Thigmotaxis. (a) Mean swim speed (±SEM) across hidden,
reversal, and visible days for males and females. No significant differences were
observed. (b) Mean proportion thigmotaxis (±SEM) across hidden, reversal, and visible
days for males and females. Ketamine males displayed a significant increase in
thigmotaxis for hidden, reversal, and visible days while the phaclofen males displayed a
significant increase on visible days. No differences were observed in the females. * =
Significantly different from saline, p > 0.05.
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Tail Flick
Tail flick (Figure 11) was performed to examine nociception differences between
treatment groups following the completion of the Morris water maze. No significant
differences were observed between treatment groups for males (One-way ANOVA; F(3,51)
= 0.903, p = 0.446) or females (F(3,31) = 0.691, p = 0.565) indicating no nociceptive
changes may be related to any differences in the above data.
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Figure 11. Tail Flick Latency. Mean latency (±SEM) to remove tail from hot water. No
differences were observed between treatment groups for males or females.
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Tissue Analysis
SDS-PAGE Western Blotting
Protein levels of multiple specific receptor subtypes relating to GABA and
NMDA signaling in the cortex were analyzed via SDS-PAGE/Western blotting. No
significant differences were observed between treatment groups in the protein levels of
either of the identified subtypes of the GABAB1 receptor subunit (1a or 1b; Figure 12a)
for males (1a: F(3,46) = 1.090, p = 0.363; 1b: F(2,46) = 0.591, p = 0.624) or females (1a:
F(3,41) = 0.863, p = 0.468; 1b: F(3,41) = 2.639, p = 0.062). Separate analyses were
performed to examine differences in only the animals treated with the GABAB ligands
compared to saline. Baclofen and phaclofen treated males did not exhibit any differences
in protein levels of either of the GABAB1 (1a and 1b) receptor subunit (1a: F(2,33) = 0.666,
p = 0.521; 1b: F(2,32) = 0.506, p = 0.607). A significant increase was observed in the
protein levels of the 1b receptor subunit in the phaclofen treated females (F(2,33) = 6.323,
p = 0.005; Tukey post hoc for saline versus phaclofen, p = 0.004) while no differences
were detected for the 1b receptor subunit in the post hoc analyses for baclofen treated
females (Tukey post hoc for saline versus baclofen, p = 0.192). Additionally, no
differences were detected in the 1a receptor subunit for the baclofen or phaclofen treated
females (F(2,32) = 0.564, p = 0.574).
Evaluation of GABAB2 receptor protein levels in the cortex (Figure 12b) did not
reveal any significant differences in the males (F(3,59) = 0.930, p = 0.432). However, the
female phaclofen group displayed a significant increase in expression level GABAB2
(F(3,41) = 4.919, p = 0.005; Tukey post hoc for saline versus phaclofen, p = 0.003). No

56

differences were found for GABAAα5 protein levels (Figure 12c) between the treatment
groups in males (F(3,44) = 0.523, p = 0.669) or females (F(3,38) = 0.471, p = 0.704).
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Figure 12. GABA Receptor Protein Levels. (a) Proportion (±SEM) and representative
blots of GABAB1a and GABAB1b protein levels normalized to β-Actin from the cortex. No
differences were observed between the male treatment groups. Phaclofen treated females
displayed increased GABAB1b protein levels compared to controls.# = Significantly
different from saline (baclofen and phaclofen in analysis only), p < 0.05. (b) Proportion
(±SEM) and representative blots of GABAB2 protein levels normalized to β-Actin from
the cortex. No differences observed between male treatment groups. Phaclofen treated
females displayed a significant increase in GABAB2 protein levels. * = Significantly
different from saline, p < 0.05. (c) Proportion (±SEM) and representative blots of
GABAα5 protein levels normalized to β-Actin from the cortex. No differences were
observed between males and females.
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Protein levels for GAD67 (Figure 13a) were not significantly different between
treatment groups for males (F(3,50) = 0.568, p = 0.639) or females (F(3,36) = 0.611, p =
0.612). However, the literature suggests a difference in GAD67 protein levels between
males versus females related to developmental maturation, therefore additional analysis
were conducted to directly compare GAD67 protein expression in males and females in
the same treatment groups (Figure 13b). A significant increase in the GAD67 protein
expression was observed for the phaclofen treated females compared to the phaclofen
treated males (F(1,20) = 6.505, p = 0.019) and for the ketamine treated females compared
to the ketamine treated males (F(1,22) = 9.601, p = 0.005). No differences were seen
between the male and female saline groups (F(1,18) = 0.047, p = 0.831) or between the
male and female baclofen groups F(1,22) = 1.577, p = 0.222).
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Figure 13. GAD67 Protein Levels. (a) Proportion (±SEM) and representative blots of
GAD67 protein levels normalized to β-Actin from the cortex. No significant differences
were observed between treatment groups for males or females. (b) Proportion (±SEM) of
GAD67 protein levels normalized to the males. A significant increase was observed for
the ketamine treated females compared to ketamine treated males as well as a significant
increase for GAD67 in the phaclofen treated females compared to phaclofen treated
males. * = Significantly different from males, p < 0.05.
The evaluation of the NR2B subunit of the NMDA receptor protein levels (Figure
14a) revealed no significant differences between treatment groups for males (F(3,51) =
0.387, p = 0.763) or females (F(3,36) = 1.151, p = 0.342). Phaclofen treated females did
displayed a significantly higher level of the kalirin 5 protein isoform compared to the
other female treatment groups (Figure 14b; F(3,36) = 4.354, p = 0.010; Tukey post hoc for
saline versus phaclofen, p = 0.008). No significant differences were found in the other
kalirin isoforms for the females (Figure 14b; kalirin 7: F(3,36) = 1.208, p = 0.321; kalirin 9:
F(3,36) = 0.838, p = 0.482; kalirin 12: F(3,36) = 0.542, p = 0.656) and no differences were
found in protein levels for any of the kalirin isoforms for the males (kalirin 5: F(3,50) =
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0.880, p = 0.458; kalirin 7: F(3,50) = 0.465, p = 0.708; kalirin 9: F(3,50) = 0.497, p = 0.686;
kalirin 12: F(3,50) = 1.255, p = 0.300).
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Figure 14. NR2B and Kalirin Protein Levels. (a) Proportion (±SEM) and representative
blots of NR2B protein levels normalized to β-Actin from the cortex. No significant
differences were observed. (b) Proportion (±SEM) and representative blots of kalirin
protein levels normalized to β-Actin from the cortex. A significant increase was observed
for kalirin 5 isoform in phaclofen treated females. * = Significantly different from saline,
p < 0.05.
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CHAPTER 5
DISCUSSION
Administration of ligands that alter the function of GABAB or NMDA receptor
function during a critical period in early brain development produced a sizable change in
behavior in adulthood. The early life alterations in GABAB and NMDA receptor
signaling also produced a change in several proteins in the brain. Specifically,
administering ketamine on PND 7, 9, and 12 (Hypothesis 1) disrupted responses in PPI
and performance in the Morris water maze. Additional changes were observed in protein
expression of GAD67 in males versus females. The administration of GABAB ligands
(baclofen or phaclofen) in development (Hypothesis 2) altered acoustic startle responses,
PPI, performance in the Morris water maze, and the expression of multiple proteins
related to GABAeric signaling as well as a protein implicated in synapse formation.
These data represent the first reports of a lifelong change in both behavioral and
biochemical processes associated with early life GABAB receptor function. The deficits
observed differed based on gender and the specific behavioral task or protein.
The data in these studies demonstrate behavioral alterations in acoustic startle
response and PPI in adulthood from the transient enhancement or blockade of the
GABAB receptor system during development. These findings also lend evidence to the
importance of these receptors during early brain development. Inhibitory tone mediated
through GABAB and NMDA receptors in adulthood is necessary for the prepulse to
reduce the acoustic startle response in PPI. The acoustic startle response is a simple,
sensorimotor reflex in the presence of fear (Koch & Schnitzler, 1997). In this experiment,
the male and female treatment groups displayed different behavior in their acoustic startle
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responses. The male baclofen group displayed an enhanced startle response across
multiple startle stimuli whereas the female animals administered baclofen displayed a
decrease in the startle response. The male ketamine group did not display an increase in
startle response across startle intensities (RM-ANOVA not significant versus saline) and,
therefore, we cannot state that they exhibited an increase in startle response overall
despite an increase in startle for the 100 dB startle stimulus. While no differences were
observed in the male phaclofen group, the female phaclofen group displayed a significant
reduction in startle response across intensities and, in particular, at the 120 dB level.
Decreases in acoustic startle response are typically observed after habituation or
sensitization after repetitive presentations (Pilz & Schnitzler, 1996). In our experimental
methods, the stimuli are only presented five times randomized throughout the session
thus insufficient for habituation or sensitization. Based on this, the increase in acoustic
startle response in the baclofen male group as well as the reduction seen in both the
baclofen and phaclofen females likely represent a gender dependent disruption to GABA
signaling involved in the sensorimotor circuitry.
Assessing the influence of multiple temporal gaps (interstimulus intervals; ISI)
between the prepulse and the startling stimulus allows for the ability to parse discrete
regions and transmitter systems involved in the multisensory PPI circuitry. The
nonstartling prepulse inhibits the reflexive response to a startling stimulus if it precedes
the startling stimulus between 10-1000 ms (Hoffman & Ison, 1980). By manipulating the
interval between the prepulse and startle stimulus (ISI), differing neurotransmitter
systems and brain regions are involved (Hoffman & Ison, 1980; Swerdlow et al., 2001;
Yeomans et al., 2010). NMDA receptors located in the prefrontal cortex and the
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hippocampus mediate the inhibition of the prepulse between ISIs of 100-500 ms
(Swerdlow et al., 2001). Both ionotropic and metabotropic GABA receptors also
influence the inhibition of the startle response. PPI occurring at shorter ISIs (starting at
20 ms) are principally governed by GABAA receptors due to the fast acting nature of
these ionotropic channels (Yeomans et al., 2010). Metabotropic GABAB receptors exhibit
a longer latency to activate but induce a longer lasting inhibitory effect that can impact
PPI over a wide range of ISIs beginning at approximately 40 ms ranging to as much as
500 ms (Yeomans et al., 2010). The combination of GABAA and GABAB receptors allow
for PPI over the entire range of intervals. The reduction in PPI in the 100 ms ISI trials in
females administered baclofen, phaclofen, and ketamine with no difference in the male
animals suggest that the females may be more sensitive to the subtle changes in these
receptor systems during early brain development. Interestingly, the reduction in PPI
across multiple prepulse intensities (see Figure 3) is typically seen in patients with
schizophrenia and animal models of schizophrenia (Bolton et al., 2012; Cilia et al, 1997;
Mansbach and Geyer 1991; Sabbagh et al., 2012; Swerdlow et al., 1998). One can argue
that the deficits displayed by the female baclofen and phaclofen in the PPI with 100 ms
ISI may be due to the reduction of the acoustic startle response. To a certain extent, the
startle response might have contributed to the deficits seen in the PPI with 100 ms ISI but
there were no differences in the female baclofen group in the PPI with 40 ms ISI making
it unlikely that the PPI deficits are an artifact of the reduced startle response.
The lack of reduction and borderline enhancement of the startle response in PPI is
extremely rare. More compelling is that at the 40 ms ISI for both the phaclofen treated
males and females exhibited this deficit, and this is the only difference shared by the
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males and females in this study. This indicates that, following GABAB receptor
antagonism in early life, not only did the animals fail to display the normal reduction in
startle response in the presence of a prepulse, but in some animals, there was an increase
in the startle response on trials that contained the prepulse. Few reports indicate a change
similar to those observed with limited data indicating only select stimulants can produce
this effect (Ashare et al., 2010; Gould et al., 2005). Knockout mice with reduced
expression of GABAB1 receptors also display an enhanced response with the presence of
the prepulse (Prosser et al., 2001). However, these mice also experience seizures and
resemble a model of epilepsy. Further, homozygous knockout of GABAB1 leads to
premature death. It is plausible that the reduction of GABAB receptors in the knockout
study may lead to a compensatory gain in systems that affect the PPI circuitry. Although
our experiment only transiently blocked GABAB receptors at brief intervals in early brain
development, it is clear that the alteration in GABAB receptor function did alter circuits
involved in PPI in a similar way as in the knockout study. These data further imply the
importance of normal functioning of the GABAB receptors during brain development.
The spatial learning and memory results from the Morris water maze revealed
some interesting findings. The importance of NMDA receptors during adulthood in
learning the hidden platform location using spatial cues have been observed in numerous
studies (Amaral & Witter, 1991; Moser, Moser, & Andersen, 1993; Sabbagh et al., 2012).
Multiple studies have demonstrated that the administration of NMDA receptor
antagonists induce deficits in spatial learning and memory (Didriksen, Skarsfeldt, & Arnt,
2007; Moosavi et al., 2012; Sabbagh et al., 2012). In this experiment, the male ketamine
group displayed deficits locating the hidden platform across training days indicating
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impairment in spatial learning; however, the selective search during the probe trial
suggests they did learn the location using a spatial strategy. There are multiple nonspatial as well as spatial strategies a subject can use to navigate this maze. The most
efficient spatial strategy is to immediately orient to the spatial cues in the room once
placed in the water and swim directly to the hidden platform location, an approach
commonly seen in controls. A less efficient strategy is a mixture of procedural and spatial
where the subject explores the maze before locating a specific position then orients itself
to find the hidden platform location (Vorhees & Williams, 2006). Based on the male
ketamine group latencies, the selective search during the probe trial, and the high
thigmotaxis, a possibility exists that these animals did not immediately attend to the
spatial cues once placed in the maze but instead swam around the perimeter before
orienting to the general area where the platform was located. This indicates that postnatal
administration of ketamine to male animals produced a subtle deficit compared to the
controls in acquiring the location of the hidden platform location but based on the
selective search during the probe, the animals were able to solve the task. Our data are
consistent with previous studies administering an alternative NMDA receptor antagonist
(PCP) during the same developmental time period (PND 7, 9, and 11) in which PCP
administration demonstrated robust deficits acquiring the hidden platform location across
days and significantly increased thigmotaxis for male animals but no differences were
observed for the females (Andersen & Pouzet, 2004). PCP binds the NMDA receptor for
a longer period of time compared to ketamine (Zukin & Zukin, 1979) which may account
for more robust deficits observed in developmental PCP administration. Therefore, the
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data from our experiment demonstrate that impairments in spatial learning and memory
can result from a subtle disruption in NMDA receptor function during development.
Few studies have specifically investigated and used ligands that target GABAB
receptors in spatial learning and memory tasks. Although there are no other studies to
compare the effects of GABAB receptor alteration in development to adulthood
performance in the Morris water maze, we did not find any differences in the acquisition
of the hidden platform training for the baclofen or phacofen treated male animals.
However, the male baclofen group failed to display a selective search during the probe
trial. Equivalent performance throughout training and a lack of a selective search during
the probe trial does indicate an impairment in learning the task (Beiko, Candusso, &
Cain, 1997; Kinney, Starosta, & Crawley, 2003; Wolfer et al., 1998). One possibility is
that the baclofen treated males were using a non-spatial strategy such as swimming a
specific distance from the wall of the maze and eventually bumping into the hidden
platform (Beiko, Candusso, & Cain, 1997; Kinney, Starosta, Crawley, 2003). Without
adopting a spatial strategy using the cues to solve the task would explain the nonselective
search. For the female data, the hidden platform training data suffered considerable
variability which may have influenced the lack of a difference between treatment groups.
Both the female saline and ketamine group did not display a selective search during the
probe trial but it is difficult to interpret the data for the ketamine group when the controls
failed to demonstrate learning the spatial task. Numerous studies have indicated greater
variability in female animals performance in the water maze (Andersen and Pouzet, 2004;
Beiko et al., 2004; Berger et al., 2006; Frick et al., 2000; Wang et al., 2001). Estrogen
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levels have been demonstrated to influence learning strategy in tasks like the Morris
water maze which may explain the females’ behavior (Chesler & Juraska, 2000).
Emotional learning and memory was examined using trace cued and contextual
fear conditioning. All treatment groups froze equivalently after the CS-US presentations
on training day, indicating equivalent effects of training and no differences were
observed during the initial cued fear or contextual fear sessions. All of the male and
female groups displayed similar extinction to the fear associations as demonstrated by the
reduction of fear behavior across days. Our laboratory has previously demonstrated
alterations in ketamine or GABAB receptor function in adulthood alters the cued fear
association (Bolton et al., 2012; Heaney et al., 2012). Additionally, following the
administration of ketamine in adult animals an increase in protein levels specific to the
postsynaptic subunit (1b) of the GABAB receptor was observed in the amygdala (Bolton
et al., 2012). This suggests an interaction between changes in NMDA receptor function
and GABAB receptors in fear conditioning (Bolton et al., 2012). Diminished NMDA
receptor function results in decreased excitation of GABAergic interneurons thus
diminished GABA release and an alteration in GABA receptors (Bolton et al., 2012;
Zhang, Behrens, Lisman, 2008). A reduction in NMDA receptor activity is hypothesized
to be involved in the pathophysiology of schizophrenia so it is logical to determine if a
change in GABAB receptors produces similar behavioral alterations as a change in
NMDA receptors as it relates to this disorder. Separate experiments performed in our
laboratory investigating GABAB receptor function associated with CCF in adult animals
revealed impaired extinction of the learned association in baclofen administered adult
animals (Heaney et al., 2012). Therefore, it has been demonstrated that ketamine and
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baclofen produce deficits in the trace cue fear association which relies on both the
amygdala and hippocampus (Bolton et al., 2012; Heaney et al., 2012). Since NMDA
antagonists induce a change in GABAB receptor levels and both NMDA antagonists and
GABAB agonists produce deficits in fear learning, it is important to investigate the
adulthood behavioral effects of postnatal alteration of these neurotransmitter systems as it
relates to CCF. An interesting observation in this current experiment is that the phaclofen
treated female group displayed a decrease in freezing to the CS following the reminder
session compared to the controls (Figure 8a). Since there were no differences in freezing
before the reminder trial, this may indicate that the phaclofen females did not exhibit
equivalent reinstatement of the fear association compared to controls. Reinstatement is
the recovery of the fear response following a post-extinction presentation of the CS-US
(Kim & Richardson, 2007). In neurobiological models of extinction as well as studies
that demonstrate impaired extinction in rats with medial prefrontal cortex (mPFC)
lesions, it is theorized that the mPFC inhibits the amygdala by activating GABA
interneurons during the expression of extinction (Hobin, Goosens, & Maren, 2003;
Morgan, Schulkin, & LeDoux, 2003; Quirk et al., 2000; Santini et al., 2004; SotresBayon, Cain, & LeDoux 2006). Adding to this, current neurobiological models of
extinction maintain that the hippocampus modulates the expression of learned fear or
extinction by inhibiting or exciting the mPFC (Hobin, Goosens, & Maren, 2003; Kim &
Richardson, 2007). The CS-US reminder triggers the hippocampal inhibition of the
mPFC, preventing the mPFC from inhibiting the amygdala following extinction. From
this model, we can infer from the reinstatement deficit observed in the phaclofen treated
females that disrupted GABA signaling within the hippocampus-mPFC-amygdala
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network may have contributed to a reduction in reinstatement of the conditioned fear.
While this change is subtle, it does indicate an alteration in Pavlovian learning as a result
of phaclofen administration in early life.
In order to examine if alterations in specific proteins may be related to the
behavioral changes observed in the present experiments, we performed SDS-PAGE
directed at multiple GABA, NMDA, and associated targets in all groups. We also
investigated if any changes were observed in the kalirin protein that is associated with
synapse formation and remodeling and has also been found to be altered in schizophrenia.
Cortex samples were evaluated based on previous literature indicating alterations in
GABAergic function being related to deficits in behavioral tasks and patient post-mortem
tissue in this region (Fatemi, Folsom, Thuras, 2011; Guidotti et al., 2000; Ishikawa et al.,
2005; Swerdlow et al., 2001; Woolley et al., 2013). The GABAB receptor is composed
two distinct subunits, GABAB1 and GABAB2. Distinct GABAB1 isoforms have been
determined to be specific to either the presynaptic (1a) or postsynaptic (1b) expression
(Steiger et al., 2004). The phaclofen treated females displayed a significant increase in
the postsynaptic (1b) isoform of the GABAB receptor. Combined with the increased
expression in the GABAB2 receptor subunit for the phaclofen treated females, these data
indicate there may be an overall increased expression of postsynaptic GABAB receptors.
This suggests that an increase in the expression of postsynaptic GABAB receptors
resulted from the brief antagonism of GABAB receptors during development. An increase
in postsynaptic receptors in the phaclofen treated females may be related to the deficits
observed in the acoustic startle response and PPI at multiple intervals. The
neurotransmitter acetylcholine is necessary to produce the startle response in both the
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acoustic startle and PPI and is regulated by inhibitory circuits (Swerdlow et al., 200l;
Yeomans et al,. 2010). The decrease in PPI observed indicates a lack of reduction in the
startle response in the presence of the prepulse. These data, coupled with the increase in
postsynaptic GABAB receptors, may reflect diminished GABA tone thus a lack of
inhibition on cholinergic neurons. However, the extent to which this increase in protein
resulted in functional GABAB receptors remains to be determined as well as the time
point at which this increase occurred (in development, adolescence, or adulthood).
We investigated other GABA related proteins that have been implicated in PPI
and schizophrenia as well as those that may be related to a change in GABA signaling.
GABAAα was examined for protein differences between treatment groups as a reduction
has been demonstrated following PPI deficits, similar to the ones observed in this study
(Hauser et al., 2005). However, no differences were seen in the GABAAα5 receptor, which
indicates the early life treatment did not induce a change in all GABAergic signaling
targets.
Evidence suggests that increases in GAD67 levels positively correlate with
GABA release. Although no differences existed between treatment groups within each
gender, we examined if the treatment had differential effects comparing genders.
Changes in GAD67 mRNA are influenced by steroid hormones such as progesterone and
estrogen (McCarthy et al., 1995; Perrot-Sinal, Davis, McCarthy, 2001; Searles et al.,
2000). However, there are conflicting reports on GAD67 expression as either being
increased or decreased in the presence of estrogen (McCarthy et al., 1995; Souza et al.,
2009). Based on the sexually dimorphic expression of GAD67, we examined whether the
effect of treatment may influence expression of this protein between genders. The data
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indicated a significant increase in the females when normalized to males of the same
treatment, indicating a difference between gender in the ketamine and phaclofen treated
animals. Studies demonstrate that GABA exerts a negative feedback effect on the
expression of GAD67 in vivo and in vitro and GAD67 is particularly sensitive to changes
in GABA (Rimvall & Martin, 1994). An increased expression in GAD67 protein may
indicate a reduction in GABA levels in the cortex. The increased expression of GAD67 in
the ketamine treated females compared to ketamine treated males may explain the sex
differences observed in PPI with 100 ms ISI. Since GABA is necessary for the inhibition
of this task, altered GABA levels as indicated by increased GAD67 expression may
account for the deficit. In addition, expression of GAD67 in the phaclofen treated females
(compared to the phaclofen treated males) was increased. Based on data that indicate an
inverse relation between GAD67 protein expression and GABA levels as well as our
findings that GABAB1b and GABAB2 protein levels are increased in phaclofen treated
females, these results may indicate decreased GABA levels in the prefrontal cortex of
these animals. Reduced GABA levels would explain the PPI with 100 ms ISI deficits and
possibly the lack of reinstatement in CCF for the phaclofen treated females. The
expression of GAD67 was not changed between genders for the saline and baclofen
group which means the changes are specific to the phaclofen and ketamine treated
groups. The data suggest that the blocking either the GABAB or the NMDA receptor
during this developmental time point had a greater impact on the female developing
nervous system compared to the male.
As GABAB has been implicated in numerous processes underlying neuronal
migration and synapse formation (Ben-Ari et al., 2007; Huang, Di Cristo, & Ango, 2007;
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Gaiarsa et al., 2011; Owens & Kriegstein, 2002; Represa & Ben-Ari, 2005;), we also
investigated if changes in proteins associated with synaptogenesis and remodeling were
observed in the treatment groups. One protein in particular, kalirin, has been found to
serve a role in synapse formations and restructuring (Ma et al., 2008). Differential
expression of kalirin isoforms has also been observed in post-mortem analysis of patients
with schizophrenia. Some studies report an increase in expression (Deo et al., 2012)
while others report a decreased expression (Hill, Hashimoto, Lewis, 2006; Penzes &
Remmers, 2012) in the prefrontal cortex. In our experiment, the phaclofen treated
females displayed an increase in protein expression levels for kalirin 5. An excess of
kalirin indicates that the mechanisms involved in synapse formation are dysregulated,
which may be associated with excessive attempts to build synapses (Penzes & Remmers,
2012). This may indicate a role for GABAB receptors in regulating synapse formation
during early brain development. This can also be related to the increased expression in
the other proteins examined (postsynaptic GABAB receptors and GAD67) in that altered
function of GABAB receptors results in dysregulated synapse formation leading to
behavioral deficits in the female animals. However, this theory requires further
investigation.
The most apparent differences in the above study were reflected in the female
treatment groups. These findings were unexpected as we did not anticipate the
differences between the sexes. Few studies include females in both behavioral and
biochemical experimental conditions, especially studies that focus on animal models of
schizophrenia. Most animal studies utilize exclusively male rodents as opposed to
females unless the researchers are interested in the influence of hormones (estrogens).
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Interestingly, estrogen has been demonstrated to be neuroprotective against cellular
dysfunction and damage, which has been shown in vitro and in vivo (see Singh, Dykens,
Simpkins, 2006). Separately, studies by Woolley (1997, 1998) reveal that chronic
administration of estradiol increase NMDA receptor expression and sensitivity to
glutamate. During the proestrus phase of a rodent estrous cycle, when estrogen levels are
at their peak, the number of synapses in the hippocampus increased by 30% compared to
the estrous phase when estrogen levels are the lowest (Warren and Juraska, 1997). The
drastic change in hippocampal morphology across the rodent estrous cycle is further
complicated by the length of the cycle. The estrous cycle of a rodent is very short (four
days) and influences their behavior in multiple tasks including PPI (Koch, 1998) and
learning and memory tasks (for review, see Dohanich, 2002). Investigations using female
rodents include initial tests for phase in the estrous cycle using a variety of methods. In
this experiment, estrous phase was not examined; however, all females were housed in
the same colony room. Based on previously established studies that mammalian females
synchronize their ovarian cycles while living in close proximity (see McClintock, 1984),
we elected to not examine the phase of estrous. Instead, we pseudo randomized the pairhoused cage assignments between treatment groups in the colony room. If there were
differences in the phase of cycle between animals, we tried to minimize the effect it may
have had in one treatment group versus another. Future studies performed in our
laboratory with females will incorporate estrous phase testing to ensure all animals are in
the same phase.
In this current experiment, the hormonal regulation of developmental processes
may have played a larger role than we had initially hypothesized. Estrogen and
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progesterone receptors are abundant in brain regions involved in reproduction but they
are also found in smaller concentrations in regions such as the basal forebrain,
hippocampus, and cortex. Estrogen and progesterone binding to these receptors affect the
rates at which proteins are synthesized (Dohanich, 2003). For example, estrogen and
progesterone secreted by the ovaries or exogenously administered can alter enzymes,
receptors, transporters, and other proteins associated with glutamate and GABA signaling
(Daniel & Dohanich, 2001). During development, the estradiol concentrations are the
same in neonatal male and female animals (Amateau et al., 2004; McCarthy & Konkle,
2005; Nunez and McCarthy, 2008). Sexual differentiation appears during the first to
second week of life due to a perinatal testosterone surge in male rodents (Ravizza et al.,
2003; Galanopoulou, 2008). As it relates to the NMDA and GABA signaling, the sex
dependent change that occurs during this early period in the rodent life is the differential
expression of the neuronal Cl--extruding K+/Cl- co-transporter (KCC2; promotes chloride
extrusion). As outlined, GABA in development is excitatory when acting upon pyramidal
GABAA receptors until after the end of first postnatal week of life in a rat (Ben-Ari et al.,
1989). These effects are due to the relatively high expression of the Na2+/K+/Cl- cotransporter 1 (NKCC1; promotes Cl- entry into the cell) and the low expression of the
KCC2 which results in a high intracellular Cl- concentration (Ben-Ari, 2002; Damborsy
& Winzer-Serhan, 2012; Payne, Stevenson, Donaldson, 1996; Rivera et al., 1999). After
the first postnatal week of life in a rat, NKCC1 is downregulated and KCC2 is
upregulated, allowing Cl- to be expelled out of the cells which results in a shift of GABA
binding GABAA receptors to induce an inhibitory post synaptic potential (Ben-Ari, 2002;
Rivera, 1999). This process is sex dependent as it occurs earlier in females compared to
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males (Damborsky & Winzer-Serhan, 2012; Galanopoulou, 2008; Nunez & McCarthy,
2007). Therefore, the differences observed between males and females in the present
experiments may be due to the administration of ligands during the time this shift occurs
and the extended duration of GABA-mediated excitation in the multiple male brain
regions (Nunez and McCarthy, 2007; Galanopoulou, 2008). The administration of
GABAB and NMDA ligands during this postnatal time period would then produce
differential effects in males and females. In the current investigation, we observed
multiple deficits in female animals following changes in GABAB receptor function.
Given that the switch from excitatory to inhibitory occurred during the same time frame
as when these drugs were administered in females (as this switch happens earlier
compared to males), it is possible that alterations in receptor systems from the drug
administration presented substantial problems in the females. This may also account for
the lack of deficits in the males as the drug administration occurred prior to this switch in
depolarizing effects of GABA on GABAA receptors. The increase in inhibition during
development as seen in the females during the drug administration period may represent a
critical period that, when disrupted, results in lifelong alterations. By blocking GABAB
receptors in females, the inhibition by which they rely may have greater effects. This may
be a potential explanation for the deficits observed in this experiment and the changes in
protein expression of multiple GABA related markers. Administering GABAB ligands at
different developmental time points might further elucidate the effects of GABAB
receptors and this excitatory to inhibitory shift in early brain develop.
These experiments were performed to determine if early life changes in NMDA or
GABAB receptors would produce alterations with relevance to schizophrenia. Despite a
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lack of a comprehensive demonstration of schizophrenia deficits in these animals, several
groups did exhibit deficits related to the disorder. For the behavioral tasks, the phaclofen
and baclofen treated females as well as the ketamine treated males exhibited deficits in
the PPI with 100 ms ISI and only the ketamine male animals demonstrated subtle spatial
learning and memory deficits. Although there were increases in the protein expression of
multiple markers examined for the phaclofen treated females, our data do not agree with
the protein changes observed in the post-mortem studies except for the increase in kalirin
5. Typically, the patient population exhibits a reduction in GABAB receptor proteins,
GABAAα5, GAD67, and NR2B (Fatemi, Folsom, Thuras, 2011; Guidotti et al., 2000;
Hauser et al., 2005; Ishikawa et al., 2005; Mizukami, 2000, 2002; Zai et al., 2005)
whereas the differences observed in this study demonstrated only increased expression in
a subset of these proteins. In addition, sex differences exist in the schizophrenia patient
population. These include men exhibiting more negative symptoms compared to women
(see Leung & Chue, 2000). The results from our study comparing males versus females
do not reflect what is seen in the patient population.
Regardless of how these results relate to schizophrenia, the deficits between the
treatment groups are intriguing. A subtle alteration of these receptor systems in early
brain development produced a lifelong behavioral change as evidenced by deficits in PPI,
learning and memory, and changes in several protein levels. This study supports a role for
precise signaling of the GABAB and NMDA receptors within specific time periods in
mammalian brain development. These neurotransmitter systems are involved in
establishing early neuronal networks (Komuro & Rakic, 1993; LoTurco, Blanton, &
Kriegstein, 1991; Uhlhaas et al., 2010), and slight alterations in GABAB or NMDA
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receptor mediated signaling may be sufficient to permanently alter connectivity that
persists into adulthood. Although other neurodevelopmental studies administering
NMDA receptor antagonist produced similar and differing deficits, most use more potent
drugs such as PCP and MK-801 and some studies inject the drug for multiple consecutive
days (Andersen and Pouzet, 2004; Broberg et al., 2010; Harich, Gross, Bespalov, 2007;
Takahashi et al., 2006; Wang et al., 2001). Our study set out to examine subtle alterations
in the NMDA receptor in development rather than a robust reduction in its function. To
our knowledge, this study is the first to assess the effects in adulthood on behavioral and
specific protein levels of early postnatal administration of a GABAB receptor agonist and
antagonist. The deficits produced by both ligands establish the importance of the GABAB
receptor and pave the way for future studies to further elucidate the role of GABAB
receptors in development and their possible involvement in neurodevelopmental
disorders.
Additional investigations are required to elucidate the mechanisms involved in
disruption the GABAB and NMDA receptors in early brain development. Examining the
effects of several concentrations and multiple time points in development would aid in
the characterization of the role of these receptor systems in development. Further protein
analysis of additional brain regions and protein markers may also provide insight into the
mechanisms involved. The data from this study provide only a glimpse of the importance
of normal function of the GABAB and NMDA receptors in early brain development.
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